Category: For physicians

  • Dr. Padda beside the title card reading The Hormone Nobody Measured Is Starving Your Nerves, The Pained Brain, Chapter 4

    Screening for Hyperinsulinemia in Patients With Neuropathic Pain

    The Hormone Nobody Measured Is Starving Your Nerves | The Pained Brain, Chapter 4

    Screening for Hyperinsulinemia in Patients With Neuropathic Pain

    Screen patients with neuropathic or chronic pain for hyperinsulinemia by drawing fasting insulin together with fasting glucose so HOMA-IR is available. Glucose and HbA1c stay in range while insulin output rises, so repeat the insulin on the same platform and read it against outcome-derived thresholds as well as the manufacturer interval.

    Glucose-based screening finds dysglycemia late by design. In patients with neuropathic or chronic pain, hyperinsulinemia and the small-fiber and endothelial changes that travel with it are often established years before HbA1c crosses the prediabetes line.

    Hyperinsulinemia is the compensatory state that glucose-based screening is structurally unable to see. Fasting glucose and HbA1c stay in range precisely because insulin output is rising, so a panel that stops at glycemia reads as normal through the years in which endothelial function, small-fiber density and pain sensitivity are already changing.

    Dr. Padda’s video The Hormone Nobody Measured Is Starving Your Nerves summarizes Chapter 4 of The Pained Brain (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD). For practices evaluating Measura [Cardiometabolic and Autonomic Health Analysis], the screening questions are specific: which patients with neuropathic or chronic pain warrant an insulin-axis workup, how to interpret an unstandardized assay, and what a positive result changes.

    Can you have hyperinsulinemia without diabetes?

    In Whitehall II, future diabetes cases carried 34.2% lower HOMA2 insulin sensitivity than controls at the earliest observation, 13 years before diagnosis. Beta-cell output peaked at 92.6% of reference three years out, and fasting glucose rose from 5.47 to 5.79 mmol/L before turning sharply upward late. A Japanese health-examination cohort of 27,392 adults found insulin-sensitivity separation ten years before a prediabetes diagnosis, at fasting glucose of 91.8 against 89.6 mg/dL, placing onset more than 20 years before diagnosis in most patients.

    On hyperinsulinemic-euglycemic clamp testing, normoglycemic hyperinsulinemic subjects disposed of glucose at 6.23 mg/kg/min, statistically indistinguishable from impaired glucose tolerance at 6.37 and new type 2 diabetes at 6.19, against 11.88 in normal controls. The control group was only five people, but the conclusion does not rest on that number.

    Why isn’t fasting insulin on the standard panel, and how should it be read?

    The American Diabetes Association workgroup that compared commercial insulin methods in 2007 found among-assay variation with a median of 24% and a ceiling of 66%. Its 2010 statement concluded that no criteria existed to classify an individual as insulin resistant and proposed a sequence: standardize the assay, let research define cutoffs, then write guidelines. The first step is still unfinished. In 2025, one of twelve immunoassays matched isotope-dilution mass spectrometry, and there is still no listed reference method or certified reference material. The 2025 Standards of Care define prediabetes by glucose and HbA1c and name no fasting insulin or HOMA-IR recommendation.

    That argues for disciplined interpretation, not omission. Draw fasting insulin together with fasting glucose so HOMA-IR is available, repeat on the same platform, and read the value against outcome-derived thresholds as well as the manufacturer interval. In the Tehran Lipid and Glucose Study, cut points predicting incident diabetes were 9.16 microU/mL in men and 11.13 in women. A reference interval built from screened-healthy Brazilian adults topped out at 13.14, with medians near 6.6.

    Can hyperinsulinemia damage small nerve fibers before diabetes is diagnosed?

    The neuropathy literature has pointed at the prediabetic window for 25 years. Of 107 patients with painful sensory neuropathy labeled idiopathic, 34% had impaired glucose tolerance on a two-hour test despite normal fasting glucose and HbA1c. In a population survey of 4,002 adults, neuropathy prevalence ran 3.25%, 6.29% and 15.12% across normoglycemia, prediabetes and diabetes. In the KORA cohort, each 5 cm of waist raised the odds of incident distal sensorimotor polyneuropathy by 22%, with no modification by diabetes status.

    Detection is method-dependent. In the Heidelberg cohort, a full quantitative sensory battery identified neuropathy in 71% of prediabetic patients against 11% on the standard deficit score, conduction studies missed 58% of battery-positive cases, and hyperalgesia was present in more than half. The damage also tracks the insulin axis. Among 5,249 Danes with recently diagnosed type 2 diabetes, the adjusted prevalence ratio for questionnaire-defined polyneuropathy was 1.72 with elevated C-peptide versus 1.42 with elevated HbA1c, and in progressing diabetic neuropathy, triglycerides were the only baseline laboratory value that correlated with a 25% one-year loss of myelinated fiber density. The evidence is not unanimous; Olmsted County cohorts found no prediabetic excess of sensory symptoms or change, so this is a majority reading of the literature.

    Can pain and steroid treatment raise insulin resistance?

    The relationship runs both ways, which matters most in pain practices. Thirty minutes of experimental painful stimulation reduced insulin-stimulated glucose uptake in ten healthy men from 6.37 to 4.97 mg/kg/min, a 22% fall, with cortisol and epinephrine rising twofold to threefold. Total hip replacement reduced whole-body insulin sensitivity 43% in fasted patients and 18% with a preoperative carbohydrate drink. Two weeks of prednisolone lowered insulin sensitivity dose-dependently in healthy young men and cut insulin-stimulated capillary recruitment by 9% and 17%. Dr. Padda’s position is to have the insulin value in hand before a glucocorticoid injection, which is used as a bridge rather than the plan.

    How do you test for hyperinsulinemia, and what does a positive result change?

    Candidates include patients with painful neuropathy labeled idiopathic; chronic pain with central adiposity, elevated triglycerides or low HDL at normal glucose; fibromyalgia and migraine patients, in whom insulin resistance has been reported in some cohorts and not others; and patients facing repeated glucocorticoid exposure. Measurements matched to the mechanism:

    • Laboratory panels with fasting glucose, HbA1c and lipids, with fasting insulin requested so HOMA-IR can be calculated, and C-peptide where the insulin axis is in question.
    • Sudomotor testing, which assesses sweat-gland function mediated by distal small fibers, the fibers conduction studies do not sample.
    • Arterial stiffness and endothelial function, because selective insulin resistance impairs the nitric oxide arm; among 40 obese nondiabetic adults, flow-mediated dilation was 9.2% in the most resistant HOMA-IR tertile against 18.0% in the least.
    • Bioimpedance body composition, since central adiposity carries neuropathy risk independent of glycemic category.

    A positive finding reframes part of the pain problem as metabolic and establishes a baseline. The intervention evidence favors reducing insulin demand over lowering glucose by any route: a year of supervised exercise raised distal leg intraepidermal nerve fiber density by 1.5 fibers/mm in type 2 diabetes with no HbA1c change, while the intensive glycemic arm of ACCORD showed a hazard ratio of 0.95 for the composite including neuropathy, with weight gain, severe hypoglycemia and excess mortality. That reading is inference across trials not designed to test insulin, and it should be charted as such. Pace matters too: reported nerve injuries during rapid weight loss on newer agents clustered at a median of 3.7 kg per month.

    Documentation, fall risk and workflow

    Put the insulin-axis panel on a standing order triggered by neuropathic symptoms or a pain diagnosis with metabolic features, so the order does not depend on who sees the patient. In older patients, a small-fiber deficit is also a fall-risk data point, so pair it with the balance and memory workup described in cognitive assessment and fall prevention. Annual wellness visits and MIPS or HEDIS cardiometabolic measures can carry the documentation, as outlined in MIPS and quality reporting.

    In Dr. Padda’s practice every new patient has a fasting insulin drawn before any procedure. The share of US adults who are metabolically healthy is under 12.2% on NHANES 2009 to 2016 and under 7% on the tighter post-2021 criteria; in that clinic population it is under 3% overall and under 1% of chronic pain patients. Read the clinic numbers honestly, as practice-reported figures from our own population, not trial outcomes, and individual results vary, which is why the study-level detail sits in the book companion for Chapter 4.

    Frequently asked questions

    Is fasting insulin reliable enough to act on?

    Reliable within a platform, variable between platforms. Repeatability on a single assay is high, yet cross-platform agreement with mass spectrometry remains poor. Order it with fasting glucose, repeat it on the same laboratory platform, and interpret trends and HOMA-IR rather than one value set against another laboratory’s interval. Interpreting the report.

    Which patients with neuropathy should be screened for hyperinsulinemia?

    Those with painful neuropathy labeled idiopathic, symptoms despite normal fasting glucose and HbA1c, central adiposity or elevated triglycerides. A third of one idiopathic painful neuropathy series had impaired glucose tolerance detectable only on a two-hour challenge, and waist circumference predicted incident neuropathy regardless of diabetes status in a prospective German cohort. Selection criteria.

    Does a normal nerve conduction study rule out metabolic neuropathy?

    No. Conduction studies sample large fibers, while metabolic injury typically begins in small fibers. In prediabetic patients studied at Heidelberg, conduction missed 58% of the neuropathy found by a full sensory battery. Small-fiber measures such as sudomotor testing sample a different fiber population and should be read alongside the examination rather than in place of it. Specialty applications.

    How do these results get into the chart?

    Results return to the ordering physician as a report for interpretation. Laboratory values and sudomotor and vascular findings can be filed as discrete results linked to the problem list, which is what makes serial comparison and quality documentation practical over time. Getting diagnostic results into the chart.

    Should the insulin finding be discussed before a steroid injection?

    It belongs in the informed discussion. Two weeks of prednisolone reduced insulin sensitivity and capillary recruitment dose-dependently in healthy men, and pain itself induces acute insulin resistance. A documented baseline lets the patient see why terrain repair accompanies the injection rather than following it. High insulin with normal blood sugar.

    How do you know you have hyperinsulinemia?

    Only by measuring insulin. Fasting glucose and HbA1c stay in range precisely because insulin output is rising, so a glucose-only panel reads as normal. Draw fasting insulin together with fasting glucose so HOMA-IR can be calculated, add C-peptide where the insulin axis is in question, and repeat on the same laboratory platform, because commercial insulin assays disagree by a median of 24%.

    How do you treat hyperinsulinemia?

    By lowering the demand for insulin, not just the glucose number. A year of supervised exercise raised leg nerve fiber density by 1.5 fibers per millimeter in type 2 diabetes with no change in HbA1c, while intensive glucose lowering in ACCORD barely moved the composite that included neuropathy and brought weight gain and severe hypoglycemia. Pace matters: reported nerve injuries during rapid weight loss clustered at a median of 3.7 kg per month.

    Build the insulin-axis workup into your practice

    Learn how the Measura protocol fits a pain, primary care or endocrine workflow, from standing orders to report interpretation.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet, 373(9682), 2215–2221. https://doi.org/10.1016/S0140-6736(09)60619-X
    • Yang, G., Li, C., Gong, Y., Fang, F., Tian, H., Li, J., & Cheng, X. (2015). Assessment of Insulin Resistance in Subjects with Normal Glucose Tolerance, Hyperinsulinemia with Normal Blood Glucose Tolerance, Impaired Glucose Tolerance, and Newly Diagnosed Type 2 Diabetes (Prediabetes Insulin Resistance Research). Journal of Diabetes Research, 2016, 9270768. https://doi.org/10.1155/2016/9270768
    • Marcovina, S., Bowsher, R. R., Miller, W. G., Staten, M., Myers, G., Caudill, S. P., Campbell, S. E., & Steffes, M. W., for the Insulin Standardization Workgroup (2007). Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup. Clinical Chemistry, 53(4), 711–716. https://doi.org/10.1373/clinchem.2006.082214
    • Rohlfing, C., Petroski, G., Hatten-Beck, M., Hanson, S., Hoofnagle, A. N., Little, R. R., & Kabytaev, K. (2025). The current status of serum insulin measurements and the need for standardization. Clinical Chemistry and Laboratory Medicine, 63(12), 2442–2446. https://doi.org/10.1515/cclm-2025-0552
    • Ghasemi, A., Tohidi, M., Derakhshan, A., Hasheminia, M., Azizi, F., & Hadaegh, F. (2015). Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran Lipid and Glucose Study. Acta Diabetologica, 52(5), 905–915. https://doi.org/10.1007/s00592-015-0730-3
    • Singleton, J. R., Smith, A. G., & Bromberg, M. B. (2001). Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care, 24(8), 1448–1453. https://doi.org/10.2337/diacare.24.8.1448
    • Kopf, S., Groener, J. B., Kender, Z., Fleming, T., Bischoff, S., Jende, J., Schumann, C., Ries, S., Bendszus, M., Schuh-Hofer, S., Treede, R.-D., & Nawroth, P. P. (2018). Deep phenotyping neuropathy: An underestimated complication in patients with pre-diabetes and type 2 diabetes associated with albuminuria. Diabetes Research and Clinical Practice, 146, 191–201. https://doi.org/10.1016/j.diabres.2018.10.020
    • Christensen, D. H., Knudsen, S. T., Gylfadottir, S. S., Christensen, L. B., Nielsen, J. S., Beck-Nielsen, H., Sørensen, H. T., Andersen, H., Callaghan, B. C., Feldman, E. L., Finnerup, N. B., Jensen, T. S., & Thomsen, R. W. (2020). Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort. Diabetes Care, 43(6), 1266–1275. https://doi.org/10.2337/dc19-2277
    • Greisen, J., Juhl, C. B., Grøfte, T., Vilstrup, H., Jensen, T. S., & Schmitz, O. (2001). Acute pain induces insulin resistance in humans. Anesthesiology, 95(3), 578–584. https://doi.org/10.1097/00000542-200109000-00007
    • Singleton, J. R., Marcus, R. L., Jackson, J. E., K Lessard, M., Graham, T. E., & Smith, A. G. (2014). Exercise increases cutaneous nerve density in diabetic patients without neuropathy. Annals of Clinical and Translational Neurology, 1(10), 844–849. https://doi.org/10.1002/acn3.125

    Related reading

  • Dr. Padda beside the title card reading Your MRI Is Lying to You, The Pained Brain, Chapter 3

    Imaging for Low Back Pain and the Metabolic Workup the MRI Skips

    Your MRI Is Lying to You | The Pained Brain, Chapter 3

    Imaging for Low Back Pain and the Metabolic Workup the MRI Skips

    Early imaging does not help uncomplicated low back pain: six randomized trials pooling 1,804 patients found no gain in pain or function, and the ACR reserves imaging for suspected cauda equina syndrome, cancer, fracture or infection, or for failure of six weeks of treatment.

    Guideline-concordant imaging for low back pain is well defined and poorly followed. The larger gap is what goes unordered: the metabolic and vascular data that separate a symptomatic finding from an incidental one.

    Imaging for low back pain has one of the clearest evidence bases in primary care and one of the weakest adherence records. The less discussed problem is substitution: the MRI answers a structural question the patient rarely needed answered, while the metabolic and vascular data that distinguish a symptomatic finding from an incidental one go unmeasured.

    The argument is laid out in Dr. Padda’s video Your MRI Is Lying to You, drawn from Chapter 3 of The Pained Brain (Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD). For a practice considering Measura [Cardiometabolic and Autonomic Health Analysis], the relevant questions are narrower: which back and joint pain patients warrant a terrain workup, what a positive finding changes, and how to make the order reproducible.

    What are the guidelines for imaging for low back pain?

    Six randomized trials pooling 1,804 patients without indications of serious disease found that immediate imaging did not improve pain or function; the long-term pain effect was -0.04. The ACR Appropriateness Criteria describe uncomplicated acute low back pain as not warranting imaging, reserving it for suspected cauda equina syndrome, malignancy, fracture or infection, or for failure of up to six weeks of medical management and physical therapy.

    Practice diverges in both directions. Across 45 studies, 24.8% of primary care and 35.6% of emergency department back pain visits ended in imaging, and the CT and MRI share rose 53.5% between 1995 and 2015. Roughly a third of lumbar referrals lacked a red flag, while 65.6% of patients who had one were never imaged. The flags themselves perform poorly: among 1,172 consecutive primary care patients, 0.9% had serious pathology and 80.4% carried at least one flag. The Cochrane review of flags for vertebral fracture found most not useful, with age over 70 the exception at a positive likelihood ratio of 11.19.

    Does an early MRI for back pain lead to more procedures?

    Nonadherent imaging shows up as downstream procedures. In 3,022 workers’ compensation claims, less severely injured workers with an early MRI had a relative risk of 27.40 for injections and 28.35 for surgery against the no-MRI referent, and comparing early with timely MRI inside the same severity band still left a surgical relative risk of 4.38. Among 405,965 matched veteran episodes without red flags, a setting where fee-for-service incentive is largely absent, lumbar surgery within a year ran 1.48% after an inappropriate early MRI against 0.12%, and prescription opioids 35.1% against 28.6%. The last recorded pain score was marginally higher in the scanned group, 3.99 against 3.87.

    Report language compounds the effect. A stepped-wedge trial that inserted age-specific prevalence benchmarks into 238,886 spine imaging reports moved twelve-month spine-related utilization by -0.7%, a null result. In a small randomized trial, patients given a descriptive finding-by-finding account of their MRI catastrophized more and functioned worse at six weeks than patients given a clinical explanation. A printed sentence of context does not neutralize the image; the explanation delivered by the clinician is the lever with trial evidence behind it.

    Why do some spine MRI findings hurt and others do not?

    The most direct case for a terrain workup comes from the Wakayama Spine Study. Among 451 community residents with moderate radiographic canal stenosis on whole-spine MRI, symptomatic and asymptomatic residents did not differ by age, sex, smoking or body mass index (23.7 against 23.1). Diabetes separated them at an odds ratio of 3.92, present in 25.0% of the symptomatic group against 6.4%, and a low ankle-brachial index separated them at 1.36 per standard deviation. In severe stenosis nothing separated the groups. The symptomatic cell is small and the design is cross-sectional, but the selection implication is clear: at intermediate structural severity, the discriminating data sit in the blood and the arteries.

    The degenerative findings track the same terrain. Pooled Mendelian randomization estimates put genetically predicted body mass index and waist circumference at 1.26 each for disc degeneration, triglycerides at 1.08 and type 2 diabetes at 1.05. Observationally, diabetes carried 1.68 times the odds across 2,881,170 adults, settling at 1.47 once code-based database studies were removed. In Framingham, aortic calcification anterior to a vertebral level predicted disc deterioration at that level over 25 years at an odds ratio of 1.5, consistent with a disc that depends on diffusion from segmental vessels. Outside the spine, metabolic syndrome carried a relative risk of 1.72 for enlarging medial bone marrow lesions in the knee, and diabetes carried odds of 3.69 for frozen shoulder and 2.24 for rotator cuff tendinopathy.

    Which back pain patients need a metabolic workup, and which tests?

    A workable selection frame for pain, primary care and geriatrics panels: back or joint pain where imaging severity and symptoms are discordant; moderate stenosis with neurogenic or vascular claudication in the differential; pain patients with central adiposity, known dysglycemia or dyslipidemia; and any patient whose workup has been imaging-heavy and laboratory-light. The criteria are summarized in selection criteria.

    • Laboratory panels: HbA1c, fasting glucose, triglycerides and HDL cholesterol, the variables with the most direct support above.
    • Ankle-brachial index: the vascular variable that separated symptomatic from asymptomatic moderate stenosis in Wakayama.
    • Bioimpedance body composition: in 223 knee replacement candidates, bioimpedance fat mass correlated with lower pressure pain thresholds at every site, including the forehead, while body mass index correlated with none.
    • Arterial stiffness and endothelial function: a functional read on the vascular bed that avascular tissue depends on.

    What a finding changes in management

    A metabolic or vascular finding does not replace imaging when a red flag is present, and Measura performs no imaging. It changes three things. Sequencing: history, examination and laboratory data come first, the image is read last and against all three, and a needle placed for a reason the examination supplied is framed as a bridge that buys time for terrain repair rather than as the plan. Explanation: the patient hears that the report describes shape while the measured values describe risk that can be tracked. Follow-up: a repeatable baseline turns a lifestyle recommendation into a monitored intervention.

    Sleep belongs in the same conversation, because it is a behavioral input with a measurable effect on the pain threshold. Two nights of fragmented sleep lowered heat pain thresholds in healthy adults, with 34.9% of the effect mediated by monocyte inflammatory output. Work schedules and caregiving load drive that input as much as any clinical variable does, and none of it appears on a spine report.

    Documentation and workflow

    The workup is reproducible only when it is protocolized rather than remembered. A standing order keyed to a discordant-imaging or symptomatic-stenosis trigger removes the dependence on individual recall. The same data serve the annual wellness visit, where cardiovascular risk factors are already documented, and quality programs such as MIPS and HEDIS where cardiometabolic measures apply. For older patients, in whom age over 70 is the flag that carries weight for vertebral fracture, file results where the fall-prevention and memory workup already lives, as described in cognitive assessment and fall prevention. Reports return to the ordering physician, and interpreting the report covers how to read them. The evidence behind each figure is in the book companion for Chapter 3.

    Frequently asked questions

    Does a metabolic workup replace imaging for low back pain?

    No. Suspected cauda equina syndrome, malignancy, fracture or infection, and failure of about six weeks of conservative care, remain indications for imaging, and Measura performs no imaging. The workup answers a different question: why a finding common in asymptomatic adults is symptomatic in this patient. In moderate stenosis, diabetes and a low ankle-brachial index answered it when canal dimensions did not. Clinical rationale.

    Which laboratory values have the most support in degenerative spine and joint pain?

    Diabetes status or HbA1c, triglycerides, HDL cholesterol and waist circumference carry the most direct evidence. Diabetes separated symptomatic from asymptomatic moderate stenosis at an odds ratio of 3.92, and genetically predicted triglycerides and waist circumference raised the odds of disc degeneration. Fasting insulin is the upstream variable that glucose-based values miss, which is the subject of the companion piece on hyperinsulinemia. Screening for hyperinsulinemia.

    How should imaging findings be explained to the patient?

    Clinically rather than descriptively. In a small randomized trial, a factual finding-by-finding explanation produced more catastrophizing and worse function at six weeks than a clinical explanation, and printing prevalence benchmarks into reports did not change utilization. Pairing the report with measured, repeatable values gives the patient something concrete to act on. A patient-facing version of this material is available. What degenerative disc disease means.

    Can the results support the annual wellness visit?

    Yes, as documentation of cardiovascular risk factors the visit already addresses. Laboratory values, body composition and ankle-brachial index results can be recorded within the same encounter structure, and repeat measurements at later visits show whether the terrain is changing. The integration steps, including how results reach the chart, are described on the practice pages. Annual wellness visit integration.

    Where do quality measures fit?

    MIPS and HEDIS include cardiometabolic measures that the same laboratory and vascular data can support as documentation. The clinical rationale should lead: test the patients whose imaging and symptoms are discordant or whose pain sits on a metabolic background, and let documentation follow from work that was clinically indicated rather than the reverse. Quality measures that cardiometabolic testing supports.

    When should you get an MRI for lower back pain?

    When a red flag points to serious disease: suspected cauda equina syndrome, cancer, fracture or infection. Imaging also fits when up to six weeks of medical care and physical therapy have not helped. Outside those cases, six randomized trials pooling 1,804 patients found that scanning early did not improve pain or function, and an early MRI was followed by more injections, surgery and opioids.

    What is a red flag in low back pain?

    A red flag is a sign that back pain may come from serious disease, such as cauda equina syndrome, cancer, fracture or infection. On their own, the flags sort patients poorly: among 1,172 primary care patients, 80.4% carried at least one flag, yet only 0.9% had serious pathology. For vertebral fracture, age over 70 is the flag that carries real weight.

    See how the protocol fits your workflow

    Learn how Measura testing is added to a practice through standing orders, report interpretation and chart integration.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Chou, R., Fu, R., Carrino, J. A., & Deyo, R. A. (2009). Imaging strategies for low-back pain: systematic review and meta-analysis. Lancet, 373(9662), 463–472. https://doi.org/10.1016/S0140-6736(09)60172-0
    • Downie, A., Hancock, M., Jenkins, H., Buchbinder, R., Harris, I., Underwood, M., Goergen, S., & Maher, C. G. (2020). How common is imaging for low back pain in primary and emergency care? Systematic review and meta-analysis of over 4 million imaging requests across 21 years. British Journal of Sports Medicine, 54(11), 642–651. https://doi.org/10.1136/bjsports-2018-100087
    • Jenkins, H. J., Downie, A. S., Maher, C. G., Moloney, N. A., Magnussen, J. S., & Hancock, M. J. (2018). Imaging for low back pain: is clinical use consistent with guidelines? A systematic review and meta-analysis. The Spine Journal, 18(12), 2266–2277. https://doi.org/10.1016/j.spinee.2018.05.004
    • Webster, B. S., Choi, Y., Bauer, A. Z., Cifuentes, M., & Pransky, G. (2014). The cascade of medical services and associated longitudinal costs due to nonadherent magnetic resonance imaging for low back pain. Spine, 39(17), 1433–1440. https://doi.org/10.1097/BRS.0000000000000408
    • Jacobs, J. C., Jarvik, J. G., Chou, R., Boothroyd, D., Lo, J., Nevedal, A., & Barnett, P. G. (2020). Observational Study of the Downstream Consequences of Inappropriate MRI of the Lumbar Spine. Journal of General Internal Medicine, 35(12), 3605–3612. https://doi.org/10.1007/s11606-020-06181-7
    • Henschke, N., Maher, C. G., Refshauge, K. M., Herbert, R. D., Cumming, R. G., Bleasel, J., York, J., Das, A., & McAuley, J. H. (2009). Prevalence of and screening for serious spinal pathology in patients presenting to primary care settings with acute low back pain. Arthritis and Rheumatism, 60(10), 3072–3080. https://doi.org/10.1002/art.24853
    • Maeda, T., Hashizume, H., Yoshimura, N., Oka, H., Ishimoto, Y., Nagata, K., Takami, M., Tsutsui, S., Iwasaki, H., Minamide, A., Nakagawa, Y., Yukawa, Y., Muraki, S., Tanaka, S., Yamada, H., & Yoshida, M. (2018). Factors associated with lumbar spinal stenosis in a large-scale, population-based cohort: The Wakayama Spine Study. PLoS One, 13(7), e0200208. https://doi.org/10.1371/journal.pone.0200208
    • Wang, X., Gao, Z., Chen, K., Huang, C., & Li, Y. (2024). Diabetes Mellitus and Intervertebral Disc Degeneration: A Meta-Analysis. World Neurosurgery, 188, e81–e92. https://doi.org/10.1016/j.wneu.2024.05.043
    • Kauppila, L. I., McAlindon, T., Evans, S., Wilson, P. W., Kiel, D., & Felson, D. T. (1997). Disc degeneration/back pain and calcification of the abdominal aorta. A 25-year follow-up study in Framingham. Spine, 22(14), 1642-1647; discussion 1648-1649. https://doi.org/10.1097/00007632-199707150-00023
    • Meert, L., Vervullens, S., Heusdens, C. H. W., Smeets, R. J. E. M., Meeus, M., & Mertens, M. G. C. A. M. (2024). Unravelling relationships between obesity, diabetes, and factors related to somatosensory functioning in knee osteoarthritis patients. Clinical Rheumatology, 43(8), 2637–2645. https://doi.org/10.1007/s10067-024-07022-2

    Related reading

  • Title card for Pain Is Not a Diagnosis, Chapter 2 of The Pained Brain, with Dr. Padda presenting

    Preoperative Diabetes Screening Before Pain Procedures and Surgery

    Pain Is Not a Diagnosis | The Pained Brain, Chapter 2

    Preoperative Diabetes Screening Before Pain Procedures and Surgery

    Preoperative diabetes screening means drawing an HbA1c before a pain procedure or surgery, and it belongs on every patient: universal screening in one arthroplasty program found diabetes or prediabetes in more than half, with 40.9% of the diabetic patients undiagnosed. An HbA1c above 8% before lumbar surgery was tied to more complications and readmissions.

    Pain care escalates from pills to needles to the operating room, usually without one metabolic number drawn. Screening everyone shows what that omission hides.

    Preoperative diabetes screening is standard in some arthroplasty programs and missing from most pain pathways, even though the unmeasured glycemia that complicates a fusion also shapes what an epidural, a drug trial or a lifestyle program delivers. The escalation ladder in pain care usually climbs from medication to injection to surgery without a single metabolic measurement on the way up.

    Pain Is Not a Diagnosis, the Chapter 2 video of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, frames pain as a signal that raises three questions before anyone treats it: which structure, which mechanism, which terrain. For a referring or treating physician, the third question is a measurement problem, and part of the second is one too.

    How the label replaced the workup

    ICD-11 codes chronic primary pain when pain has lasted beyond three months with distress or disability and is not better accounted for by another condition. It works as a coding instrument, yet no biological criterion separates primary from secondary pain; the category is defined by what was not found. A label built from exclusion gives a clinician nowhere to go next.

    For about two decades the field, Dr. Padda’s own specialty among them, treated the pain score as the endpoint. The numeric rating became a vital sign, and a review of 600 VA visits found no quality indicator improved afterward. The incentives reinforced it: 83% of academic pain-center leaders reported administrative pressure tied to satisfaction scores, while in 51,946 nationally representative adults the most-satisfied quartile carried an adjusted mortality hazard of 1.26. A metric that rewards a quiet patient does not reward a measured one.

    How often does preoperative screening find undiagnosed diabetes?

    Screen every patient and the prevalence stops being theoretical. In a Philadelphia arthroplasty population of 1,461, diabetes was present in 20.6% and prediabetes in 38.3%, and 40.9% of the diabetic patients carried no prior diagnosis. Universal HbA1c testing before knee replacement in Hong Kong added undiagnosed prediabetes in 36.4% and undiagnosed diabetes in 1.6%. Most of those patients had been through primary care and a surgical referral without the number being drawn.

    The value predicts the result. In 4,778 elective lumbar operations, preoperative HbA1c above 8% was associated with an odds ratio of 1.81 for any complication, 1.66 for 90-day readmission and 0.64 for reaching a meaningful functional gain. In a matched analysis of 7,336 arthrodesis patients with diabetes, 30-day readmission ran 6.5% against 4.4% and 90-day reoperation 4.3% against 3.2%, with no difference after decompression alone. Across more than 3 million spine operations, metabolic syndrome carried relative risks of 1.5 for readmission and 1.6 for wound complications.

    The evidence is observational, diabetes is often a registry checkbox rather than a measured value, and one cohort of 587 hip and knee replacements found similar 12-month pain and function once BMI and comorbidity were adjusted. That study supports obesity plus multimorbidity as the operative terrain rather than HbA1c alone, which is still an argument for measuring the terrain.

    Do steroid injections raise blood sugar?

    The same body receives the injections. In a multicenter cervical epidural cohort, 92% of diabetic patients developed transient hyperglycemia, and in 18 patients measured serially, fasting glucose was elevated on day 1 and back to baseline by day 7. Bone density reductions appeared at a cumulative methylprednisolone-equivalent dose of 200 mg in a year, against real-world exposure averaging 14.7 injections per patient. An epidural used as a bridge on a patient with known metabolic status is a defensible plan. The same injection repeated on an unmeasured body is exposure without a denominator.

    Practically, a known HbA1c before a steroid procedure lets the team set a glucose-monitoring plan for the following week and track cumulative steroid dose against a bone-health baseline, instead of discovering the diabetes after the second or third injection.

    Mechanism is also unmeasured

    Physical examination alone is Level IV evidence for identifying a spinal pain generator and MRI or CT Level V, so a structural answer needs a controlled block. Mechanism is skipped even more often. Of 27 trials of neuropathic-pain drugs for back and spine-related leg pain, 59% excluded neuropathic pain or never assessed it, and only 22% enrolled patients at the probable-or-definite level. Where neuropathic pain was probable, pain fell 10.45 points on a 100-point scale; where merely possible, 5.50, though subgroup differences were not significant. In one clinic sample of 1,957 patients, 13.0% screened positive for a neuropathic component, with no correlation to pain duration.

    A validated screening questionnaire belongs in the intake. Where small-fiber involvement is suspected, sudomotor testing adds an objective read on the sweat response driven by small distal nerve fibers, which helps separate a neuropathic contribution from a purely structural one before drug selection.

    Why measure a metabolic baseline before treating pain?

    The terrain trials show pain responding in proportion to metabolic change. In 407 adults with obesity and knee osteoarthritis, semaglutide reduced knee pain by 41.7 points against 27.5 for placebo over 68 weeks with weight loss of 13.7% against 3.2%. Metformin in 107 adults with knee osteoarthritis and overweight reduced pain by 11.4 mm more than placebo. Intensive diet and exercise produced 10.6 kg of weight loss with a fall in IL-6, while the community version of the same program moved pain by only 0.6 points, and a telephone referral that changed weight by 0.4 kg changed pain not at all.

    The less obvious consequence is diagnostic. Without a baseline body composition and metabolic panel, a patient who fails a lifestyle or pharmacologic plan cannot be classified: the terrain may not have changed, or it changed and the pain generator lies elsewhere. Repeat measurement is what distinguishes a failed intervention from a failed dose. Serial values also support between-visit monitoring in chronic care.

    What should a preoperative diabetes screening order set include?

    Guidelines will not supply it. The 2022 CDC opioid-prescribing guideline runs 95 pages without mentioning HbA1c, insulin or an inflammatory marker, and the NICE chronic pain assessment section sets out 23 recommendations naming no blood test. Neither prohibits testing; both leave a vacancy that a practice has to fill with its own protocol.

    A workable protocol attaches a standing order to any referral for fusion, arthroplasty or repeated steroid injection: HbA1c and fasting glucose against the published thresholds of 6.5% and 126 mg/dL for diabetes and 5.7-6.4% and 100-125 mg/dL for prediabetes, fasting insulin and lipids through laboratory panels, bioimpedance body composition, a mood screen and a neuropathic screen. Measura [Cardiometabolic and Autonomic Health Analysis] performs and reports those measurements under physician medical direction; interpretation and management remain with the ordering and treating physicians, and results should travel to the surgeon through structured record integration. The study-level evidence is in the Chapter 2 supplement, and the mortality case for screening pain patients at all is in the physician article on metabolic screening in chronic pain. Excess weight can hide depleted muscle and micronutrients before an operation, the focus of malnutrition in obesity.

    Frequently asked questions

    Which pain patients should have diabetes screening before a procedure?

    Any patient being referred for spinal fusion, joint replacement or repeated epidural steroid injection without a recent HbA1c. Universal screening in one arthroplasty program found dysglycemia in 58.9% of patients, and 40.9% of those with diabetes were undiagnosed, so selective screening by risk factors misses a large share. Selection criteria.

    What HbA1c level changes surgical risk in spine surgery?

    In 4,778 elective lumbar operations, values above 8% carried an odds ratio of 1.81 for complications and 0.64 for achieving a meaningful functional improvement. That threshold sits well above the diagnostic line for diabetes, so it says nothing about the prediabetic range, where the value of screening is earlier detection rather than a surgical cutoff. Specialty applications.

    Should glucose be monitored after an epidural steroid injection?

    In diabetic patients the data support a plan. One multicenter cervical cohort found transient hyperglycemia in 92% of diabetic patients, and serial measurement in a smaller study showed fasting glucose elevated on day 1 and normal by day 7. Knowing metabolic status beforehand lets the treating team decide who needs closer follow-up that week. Physician questions.

    Why add body composition to a preoperative workup?

    Obesity with multimorbidity, not HbA1c alone, explained worse joint replacement outcomes in at least one adjusted cohort, and terrain trials show pain tracking metabolic change. Body composition separates fat from lean mass that BMI conflates, giving a baseline against which weight-loss or pharmacologic preparation can be judged. Interpreting the report.

    How much staff time does a screening order set add?

    Most elements are blood draws and brief measurements that fit into an existing intake or preoperative visit, and a standing order removes the need for a separate decision each time. The larger task is routing results to the surgeon and the referring physician in structured form so they are acted on. Staffing and workflow.

    Can a high A1C increase the risk of surgery?

    Yes. In 4,778 elective lumbar operations, HbA1c above 8% carried an odds ratio of 1.81 for any complication and 1.66 for 90-day readmission. In 7,336 arthrodesis patients with diabetes, 30-day readmission ran 6.5% against 4.4%, with no difference after decompression alone. Across more than 3 million spine operations, metabolic syndrome carried relative risks of 1.5 for readmission and 1.6 for wound complications.

    What A1C level means diabetes or prediabetes?

    The published diagnostic thresholds used in the order set are an HbA1c of 6.5% or a fasting glucose of 126 mg/dL for diabetes, and an HbA1c of 5.7-6.4% or a fasting glucose of 100-125 mg/dL for prediabetes. Universal screening in one arthroplasty program found prediabetes in 38.3% of patients, which is why the draw belongs on everyone referred for fusion, arthroplasty or repeated steroid injection.

    Do repeated steroid injections affect bone density?

    Bone density reductions appeared at a cumulative methylprednisolone-equivalent dose of 200 mg in a year, while real-world exposure averaged 14.7 injections per patient. A known metabolic status and a bone-health baseline before the first steroid procedure let the team track cumulative dose, instead of discovering the problem after the second or third injection. An epidural used as a bridge on a measured patient is a defensible plan.

    Measure the terrain before escalating care

    Learn how the Measura protocol attaches metabolic, body composition and nerve measurements to a surgical or procedural referral without rebuilding your workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Shohat, N., Goswami, K., Tarabichi, M., Sterbis, E., Tan, T. L., & Parvizi, J. (2018). All Patients Should Be Screened for Diabetes Before Total Joint Arthroplasty. The Journal of Arthroplasty, 33(7), 2057–2061. https://doi.org/10.1016/j.arth.2018.02.047
    • Lim, S., Yeh, H. H., Macki, M., Mansour, T., Schultz, L., Telemi, E., Haider, S., Nerenz, D. R., Schwalb, J. M., Abdulhak, M., Park, P., Aleem, I., Easton, R., Khalil, J., Perez-Cruet, M., & Chang, V. (2021). Preoperative HbA1c > 8% Is Associated With Poor Outcomes in Lumbar Spine Surgery: A Michigan Spine Surgery Improvement Collaborative Study. Neurosurgery, 89(5), 819–826. https://doi.org/10.1093/neuros/nyab294
    • Mooney, J., Nathani, K. R., Zeitouni, D., Michalopoulos, G. D., Wang, M. Y., Coric, D., Chan, A. K., Lu, D. C., Sherrod, B. A., Gottfried, O. N., Shaffrey, C. I., Than, K. D., Goldberg, J. L., Hussain, I., Virk, M. S., Agarwal, N., Glassman, S. D., Shaffrey, M. E., Park, P., … Bydon, M. (2023). Does diabetes affect outcome or reoperation rate after lumbar decompression or arthrodesis? A matched analysis of the Quality Outcomes Database data set. Journal of Neurosurgery: Spine, 40(3), 331-342. https://doi.org/10.3171/2023.9.SPINE23522
    • Lenguerrand, E., Beswick, A. D., Whitehouse, M. R., Wylde, V., & Blom, A. W. (2018). Outcomes following hip and knee replacement in diabetic versus nondiabetic patients and well versus poorly controlled diabetic patients: a prospective cohort study. Acta Orthopaedica, 89(4), 399-405. https://doi.org/10.1080/17453674.2018.1473327
    • Gogol, P., Pasztaleniec, R., Szczepaniak, R., Wiśniewski, R., Staszkiewicz, R., Sobstyl, M., Wąsik, P., & Grabarek, B. O. (2026). Clinical Outcomes of Two Institution-Specific Cervicothoracic Interlaminar Epidural Steroid Injection Protocols (C7/T1-6 mL vs. T1/T2-8 mL) in Cervical Radiculopathy: A Multicenter Retrospective Cohort Study. Journal of Clinical Medicine, 15(15), 5900. https://doi.org/10.3390/jcm15155900
    • Ward, J., Grinstead, A., Kemp, A., Kersten, P., Schmid, A. B., & Ridehalgh, C. (2024). A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain? Drugs, 84(12), 1603–1636. https://doi.org/10.1007/s40265-024-02085-6
    • Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., Wizert, A., & Kristensen, L. E. (2024). Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. The New England Journal of Medicine, 391(17), 1573–1583. https://doi.org/10.1056/NEJMoa2403664
    • Messier, S. P., Beavers, D. P., Queen, K., Mihalko, S. L., Miller, G. D., Losina, E., Katz, J. N., Loeser, R. F., DeVita, P., Hunter, D. J., Newman, J. J., Quandt, S. A., Lyles, M. F., Jordan, J. M., & Callahan, L. F. (2022). Effect of Diet and Exercise on Knee Pain in Patients With Osteoarthritis and Overweight or Obesity: A Randomized Clinical Trial. JAMA, 328(22), 2242–2251. https://doi.org/10.1001/jama.2022.21893
    • Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. MMWR. Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1

    Related reading

  • Title card for The Cost of Pain Is Paid in Years, Chapter 1 of The Pained Brain, with Dr. Padda presenting

    Metabolic Screening in Chronic Pain: Who to Test and What Changes

    The Cost of Pain Is Paid in Years | The Pained Brain, Chapter 1

    Metabolic Screening in Chronic Pain: Who to Test and What Changes

    Screen chronic pain patients whose pain limits work, self-care or activity, or who hurt at multiple sites: that pain history predicts cardiometabolic death. Fasting insulin, the triglyceride-glucose index and body composition find the risk that glucose and CRP miss.

    Pain that limits function and spreads across several sites carries mortality risk that survives adjustment. That turns the pain history into a screening trigger, not only a treatment problem.

    The case for metabolic screening with chronic pain as the trigger rests on an epidemiologic finding most workups ignore: the pain history itself predicts cardiometabolic death, while the standard pain evaluation measures almost none of the cardiometabolic terrain. In most practices the back is managed in one silo and the glucose in another, and neither silo owns the patient.

    The Cost of Pain Is Paid in Years, the Chapter 1 video of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD, makes that case for patients. For clinicians the translation is operational: which pain patients to screen, what the measurements add beyond glucose and CRP, what a finding changes, and how it is documented.

    Does chronic pain raise the risk of early death?

    In UK Biobank participants aged 40 to 69, chronic widespread pain was associated with all-cause mortality of 2.28 in men and 2.31 in women against no chronic pain, attenuating to 1.47 once body mass, activity, smoking, alcohol and diet entered the model. In an American cohort of 19,487 adults over 50 followed for two decades, activity-limiting pain carried a hazard of 1.64 unadjusted and 1.52 after sociodemographic adjustment. With cardiac, oncologic, pulmonary and diabetic disease plus BMI added, it still carried 1.33. Severe pain without functional limitation, by contrast, sat at 1.05, not significant. Interference, not intensity, is the variable worth charting.

    Site count behaves like a dose. Across 384,367 UK adults, the mortality hazard rose from 1.09 with one chronic musculoskeletal pain site to 1.46 with four. Neck or shoulder pain alone carried 1.99 for death from endocrine, nutritional and metabolic disease, in a model adjusted for age, sex, ethnicity and deprivation but not for BMI or diabetes.

    Read the attenuation carefully. When adjustment for weight, diabetes and heart disease shrinks the pain association, the absorbed variance sits in the metabolic disease. Arithmetic cannot say whether those variables confound or mediate. Clinically, the answer is the same either way: the risk lives where it can be measured.

    A Danish interdisciplinary pain center linked 6,142 patients to the national death register and found a standardized mortality ratio of 6.2, with circulatory deaths at 5.7, adjusted only for age and sex.

    Who needs metabolic screening for chronic pain?

    A practical selection rule follows from those cohorts. Consider cardiometabolic measurement in chronic pain patients who have:

    • pain that limits work, self-care or activity, regardless of the intensity score;
    • pain at multiple sites, recorded as a count rather than as the worst site;
    • central adiposity with a glucose and A1c that have been called normal;
    • a normal BMI with East Asian or South Asian ancestry, where visceral and hepatic fat run ahead of weight;
    • depression or anxiety alongside the pain, given that 39.3% of adults with chronic pain carry clinically significant depressive symptoms and 40.2% anxiety symptoms across pooled studies.

    These criteria map onto existing selection criteria and can be written as a standing order for screening, so the pain history triggers the measurement without a separate decision at every visit.

    Which blood tests find metabolic risk in chronic pain?

    Glucose is a late signal. Hyperinsulinemia, defined as fasting insulin above 10 µU/mL, was present in 41.4% of nondiabetic NHANES adults in 2017-2018, and HOMA-IR insulin resistance in 38.4%. The HOMA-IR threshold of 2.6 behind those figures is a population percentile; no consensus diagnostic cutoff exists, so serial values within one laboratory are more informative than a single reading.

    The triglyceride-glucose index is computable from labs already on file. In 3,546 Chinese adults with a mean BMI of 23.76 followed nine years, each one-unit rise predicted new severe chronic pain at 1.51, and baseline BMI did not differ between those who developed pain and those who did not, 24.06 against 23.75. In American survey data the index stayed associated with chronic pain after adjustment for BMI and diabetes status, at 1.25, and within the chronic pain group the top tertile carried 2.05 times the all-cause mortality of the bottom.

    CRP is a weak screening anchor. A visceral-fat score predicted chronic pain in 5,905 NHANES adults, with CRP mediating 7.4% of the effect, and Mendelian randomization finds no causal effect of CRP on spinal pain. Prospectively, hs-CRP alone did not predict incident chronic musculoskeletal pain, yet hs-CRP at or above 3 mg/L combined with sleeplessness carried 2.47. The marker means more read against the sleep history than read alone. The underlying model is inflammation that fails to resolve, metaflammation, supported by gene-expression work in acute low back pain whose human arm remains observational.

    What changes when a pain patient’s metabolic screen is abnormal?

    A normoglycemic patient with hyperinsulinemia, a high triglyceride-glucose index or a visceral-predominant body composition is reclassified from a pain problem with normal labs to a pain problem inside metabolic disease. That changes the plan: lifestyle and behavioral work moves from discharge advice to the core of treatment, the interval for repeat measurement is set in advance, and procedures are framed as a bridge to terrain repair rather than the whole plan.

    The evidence base for pain treatment rarely describes this patient. Half of 168 randomized trials in nonspecific low back pain excluded prior or scheduled surgery, while among 500,295 UK adults, 69.1% of those with chronic pain had at least one long-term condition and 36.2% had two or more. Guideline-derived care was built on somebody else, which is the argument for measuring the person in front of you. It takes some humility for pain medicine, Dr. Padda’s own specialty, to admit that of the twelve chronic pain modalities the American Society of Anesthesiologists lists, none addresses systemic inflammation.

    The drivers are not only biological. At age 52, pain was reported by 40% of Americans born in 1965 without a bachelor’s degree against 32% of the 1955 cohort, rising 0.6 percentage points per birth year without a degree and 0.2 with one; body mass explained about a quarter. Pain prevalence reaches 31.4% in nonmetropolitan counties. Screening that follows only symptoms will miss the populations where the gradient is steepest.

    Where Measura fits in the workflow

    Measura [Cardiometabolic and Autonomic Health Analysis] is a testing service under physician medical direction. It performs and reports measurements; diagnosis and management stay with the ordering physician. For this indication the relevant tests are laboratory panels that add fasting insulin and the lipid pattern to glucose and A1c, bioimpedance body composition to separate fat and lean compartments that BMI conflates, and arterial stiffness and endothelial function for the vascular consequence of sustained hyperinsulinemia.

    Documentation should carry the variables the cohorts validated: pain site count, whether pain limits activity, waist circumference in centimeters, fasting insulin with glucose and lipids, and a mood screen. Structured fields make those values reportable and trendable, and getting results into the record keeps them in front of the next clinician. For context, under 12.2% of US adults met full metabolic-health criteria on NHANES 2009–2016 and under 7% on the tighter post-2021 criteria; in Dr. Padda’s practice, under 1% of chronic pain patients do, practice-reported figures from our own population, not trial outcomes, with individual results that vary. The study-level detail is in the Chapter 1 supplement, and the diagnostic framework that follows is in the physician article on screening the terrain before escalating care.

    Frequently asked questions

    Which chronic pain patients benefit most from metabolic screening?

    The cohort data point to patients whose pain limits activity, who hurt at several sites, who have central adiposity with normal glucose, or who have a normal BMI with Asian ancestry. Activity-limiting pain retained a mortality hazard of 1.33 after full adjustment, and hazard rose stepwise with site count, so both belong in the selection rule. Clinical rationale.

    Why are A1c and CRP not enough?

    A1c reflects glycemia, which stays normal while insulin rises; 41.4% of nondiabetic US adults were hyperinsulinemic by 2017-2018. CRP shows no causal effect on spinal pain by Mendelian randomization and mediated only 7.4% of the visceral-fat association with chronic pain. Fasting insulin, the triglyceride-glucose index and body composition describe the terrain those markers miss. Interpreting the report.

    Does adjustment for diabetes explain away the link between pain and mortality?

    No. Adjustment attenuated the American hazard from 1.52 to 1.33 and the British ratio to 1.47, but did not eliminate it. The attenuated share sits in metabolic disease, and statistics cannot separate confounding from mediation. Either reading supports measuring the metabolic variables rather than assuming the pain is prognostically neutral. What changes for the patient.

    How does this fit into an annual wellness visit?

    The annual wellness visit already collects functional status, mood screening and a cognitive check. Adding pain site count, pain interference and waist circumference fits the same encounter, and a standing order can attach fasting insulin, lipids and body composition to patients who meet the selection rule, keeping measurement consistent across clinicians. Annual wellness visit integration.

    How should findings be documented for quality reporting?

    Record measurements as structured values rather than narrative: site count, interference, waist, fasting insulin, lipids and body composition, with dates so trends can be tracked. Structured entries support MIPS and HEDIS documentation as quality concepts and let the finding follow the patient between specialties instead of disappearing into a scanned report. MIPS and quality reporting.

    Is there a blood test for chronic pain?

    Blood tests do not replace the pain history, but several lab values track the metabolic risk that travels with it. Glucose is a late signal, while fasting insulin is not: 41.4% of nondiabetic US adults were hyperinsulinemic in 2017-2018. The triglyceride-glucose index comes from labs already on file. hs-CRP alone did not predict new chronic musculoskeletal pain, though hs-CRP at or above 3 mg/L combined with sleeplessness carried 2.47.

    What is the triglyceride-glucose index?

    It is an index calculated from fasting triglycerides and glucose, so it can be computed from labs already on file. In 3,546 Chinese adults followed nine years, each one-unit rise predicted new severe chronic pain at 1.51. Among American adults with chronic pain, the top tertile carried 2.05 times the all-cause mortality of the bottom tertile.

    Does the number of places that hurt matter?

    Yes. Site count behaves like a dose. Across 384,367 UK adults, the mortality hazard rose from 1.09 with one chronic musculoskeletal pain site to 1.46 with four. That is why the selection rule records pain as a count of sites rather than as the single worst site, alongside whether the pain limits work, self-care or activity.

    Can a chronic pain patient have metabolic disease at a normal weight?

    Yes. In the Chinese cohort, baseline BMI did not differ between people who developed severe chronic pain and those who did not, 24.06 against 23.75. In patients of East Asian or South Asian ancestry, visceral and hepatic fat run ahead of weight. Bioimpedance body composition separates the fat and lean compartments that BMI conflates, which is why a normal BMI does not end the workup.

    Add cardiometabolic measurement to the pain workup

    Learn how the Measura protocol fits a primary care or pain practice, from selection criteria and standing orders to getting structured results into the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Ruan, H., Yang, Y., & Grol-Prokopczyk, H. (2026). Which is More Predictive of Mortality-Pain Severity or Pain Interference? Evidence from 20-Year Longitudinal Data. The Journal of Pain, 40, 106192. https://doi.org/10.1016/j.jpain.2026.106192
    • Chen, L., Ferreira, M. L., Nassar, N., Preen, D. B., Hopper, J. L., Li, S., Bui, M., Beckenkamp, P. R., Shi, B., Arden, N. K., & Ferreira, P. H. (2021). Association of chronic musculoskeletal pain with mortality among UK adults: A population-based cohort study with mediation analysis. EClinicalMedicine, 42, 101202. https://doi.org/10.1016/j.eclinm.2021.101202
    • Macfarlane, G. J., Beasley, M., & Jones, G. T. (2023). Chronic pain and premature mortality in men and women, using data from UK Biobank. The Journal of Clinical Investigation, 133(5), e166949. https://doi.org/10.1172/JCI166949
    • Vaegter, H. B., Støten, M., Silseth, S. L., Erlangsen, A., Handberg, G., Sondergaard, S., & Stenager, E. (2019). Cause-specific mortality of patients with severe chronic pain referred to a multidisciplinary pain clinic: a cohort register-linkage study. Scandinavian Journal of Pain, 19(1), 93–99. https://doi.org/10.1515/sjpain-2018-0094
    • Zhou, D., Jin, F., Zhang, L., Chen, J., Tian, L., & Li, J. (2026). The Mediating Role of WBC in the Relationship Between Triglyceride-Glucose Index and Chronic Pain: Evidence From NHANES 2001-2004 Data. Pain Research & Management, 2026(1), e3793191. https://doi.org/10.1155/prm/3793191
    • Skarpsno, E. S., Mork, P. J., Nilsen, T. I. L., Steingrímsdóttir, Ó. A., Zwart, J. A., & Nilsen, K. B. (2019). The interplay between sleeplessness and high-sensitivity C-reactive protein on risk of chronic musculoskeletal pain: longitudinal data from the Tromsø Study. Sleep, 42(9), zsz127. https://doi.org/10.1093/sleep/zsz127
    • McQueenie, R., Jani, B. D., Siebert, S., McLoone, P., McCowan, C., Macdonald, S., Mair, F. S., & Nicholl, B. I. (2021). Prevalence of chronic pain in LTCs and multimorbidity: A cross-sectional study using UK Biobank. Journal of Multimorbidity and Comorbidity, 11, Article 26335565211005870. https://doi.org/10.1177/26335565211005870
    • McMasters, M., & Mora, J. (2025). Addressing Meta-Inflammation in the Comprehensive Management of Chronic Pain. Cureus, 17(10), e94863. https://doi.org/10.7759/cureus.94863
    • Aaron, R. V., Ravyts, S. G., Carnahan, N. D., Bhattiprolu, K., Harte, N., McCaulley, C. C., Vitalicia, L., Rogers, A. B., Wegener, S. T., & Dudeney, J. (2025). Prevalence of Depression and Anxiety Among Adults With Chronic Pain: A Systematic Review and Meta-Analysis. JAMA Network Open, 8(3), Article e250268. https://doi.org/10.1001/jamanetworkopen.2025.0268
    • Case, A., Deaton, A., & Stone, A. A. (2020). Decoding the mystery of American pain reveals a warning for the future. Proceedings of the National Academy of Sciences of the United States of America, 117(40), 24785-24789. https://doi.org/10.1073/pnas.2012350117

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading You Can Protect a Struggling Neuron. Here Is How, The Starved Brain, Chapter 10

    Low-Carb Diet Safety: A Physician’s Baseline and Re-Measure Plan

    You Can Protect a Struggling Neuron. Here Is How | The Starved Brain, Chapter 10

    Low-Carb Diet Safety: A Physician’s Baseline and Re-Measure Plan

    Low-carb diet safety is a baseline problem: flag patients on insulin, sulfonylureas, meglitinides, SGLT2 inhibitors or two or more antihypertensives, record autonomic, balance, cognitive and body-composition baselines, and schedule a repeat measurement. Hypoglycemia, euglycemic ketoacidosis and orthostatic falls are the predictable risks.

    The patient who quietly cuts carbohydrate arrives at the next visit with a lower glucose, a lower pressure and the same prescriptions. The workup belongs before the diet, not after the first event.

    Low-carb diet safety is a primary care problem before it is a nutrition problem. Patients read about carbohydrate restriction for metabolic and brain health, start without telling anyone, and the medication list written for their old diet keeps running. The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, closes with a chapter, and a video, You Can Protect a Struggling Neuron, that put the safety evidence ahead of the protocol for exactly that reason. For the screening physician the lesson is a sequence: identify who is at risk, record the baseline that makes adverse effects visible, and schedule the repeat that shows whether the correction is working. Measura [Cardiometabolic and Autonomic Health Analysis] supplies measurement for that sequence; it does not prescribe diet or manage medication.

    What are the risks of a low-carb diet for patients on medication?

    • Hypoglycemia on insulin, sulfonylureas and meglitinides. The 2025 ADA Standards call for consistent medical oversight of very-low-carbohydrate eating and recognize that diabetes medications may need adjustment to prevent hypoglycemia. Practical guides published in 2019 and 2021 describe dose reductions at initiation rather than after the first low reading. In a remotely supervised cohort of 262 adults with type 2 diabetes, sulfonylurea use went from 23.7% to 0% in a year under daily glucose review. No study has put a clock on the first hypoglycemic event; Dr. Padda reports seeing it within days in his own patients.
    • Euglycemic ketoacidosis on SGLT2 inhibitors. The FDA relabeled the class in December 2015 after 73 reports; median reported glucose was 211 mg/dL, and a low-carbohydrate diet was named among the risk factors. In FAERS, 71% of reports with laboratory data were euglycemic. Among 208,757 new users, ketoacidosis carried HR 2.85 against DPP-4 inhibitors. Published cases include patients sent home because hyperglycemia was not marked.
    • Orthostatic symptoms on antihypertensives. Sodium loss dominates the first week. On a metabolic ward, symptomatic orthostatic hypotension occurred in 7 of 7 obese adults on a ketogenic protein diet. In DiRECT, among 69 participants who stopped all antihypertensives at the start of a formula diet, dizziness affected 36% and 27.5% needed a drug restarted, most of them previously on two or more.

    Who should be flagged before starting a low-carb diet?

    The list is short: patients on insulin, a sulfonylurea or a meglitinide; anyone on an SGLT2 inhibitor; two or more antihypertensives; pregnancy or lactation; kidney, liver, gallbladder or pancreatic disease; a history of disordered eating; a suspected inherited disorder of fat metabolism, where the diet is contraindicated; and moderate or advanced dementia. The 2025 ADA Standards state that very-low-carbohydrate plans are not currently recommended in pregnancy or lactation, in children, in kidney disease, or in people with or at risk for disordered eating. A flag raised at the metabolic or cognitive workup is easier to act on than one raised in the emergency department, and standing orders make that flag reproducible across a panel.

    Why does a low-carb diet cause dizziness and falls?

    The orthostatic data expose a measurement gap. A seated blood pressure at a routine visit says little about how an older patient on two or three antihypertensives will tolerate a week of sodium and water loss. Cardiac autonomic reflex tests and heart rate variability characterize autonomic regulation of heart rate and blood pressure, and vestibular and balance testing documents balance before a change known to produce dizziness on standing. A patient who already has impaired autonomic regulation or a balance deficit is the one in whom a predictable orthostatic drop is most likely to end on the floor. Recording that baseline ties the metabolic plan to fall prevention, the pairing outlined in cognitive assessment and fall prevention.

    Cognitive and body-composition anchors

    The USPSTF grades cognitive screening of asymptomatic adults over 65 as insufficient evidence, and the AAN guideline that recommended validated assessment has since been retired. Neither addresses a personal baseline in a patient with a concern who is about to change a major metabolic input. Cognitive assessment in that setting is not population screening; it is the comparison point for the next score.

    Stage changes the calculation. In the KDRAFT pilot, 1 of 7 participants with very mild Alzheimer’s withdrew, and all 4 with moderate disease withdrew, each citing caregiver burden. The 2024 ESPEN guideline does not recommend routine ketogenic diets in dementia and treats malnutrition screening as essential. In 37,717 Korean adults newly diagnosed with dementia, being underweight after diagnosis carried HR 1.57 for death. Bioimpedance body composition gives a lean-mass reference, so weight loss in an older patient is read by compartment rather than by the scale.

    When should labs be rechecked after starting a low-carb diet?

    Laboratory panels drawn before the change should report fasting insulin as a number. In Whitehall II, modeled insulin sensitivity fell steeply over the five years before diabetes while glucose inflected only three years before. A single fasting value has limits: in 4,185 people with normal glucose tolerance it was of limited value for detecting dynamic hyperinsulinemia. The triglyceride-to-HDL ratio performed poorly in 98 overweight African American adults, AUC 0.56 against 0.85 for fasting insulin, so cut-points derived in white cohorts should not be transferred. Every marker then keeps its own clock:

    • About ten weeks. In the supervised cohort, 84% of the one-year HbA1c fall, 90% of the fasting-glucose fall and 73% of the fasting-insulin fall were present by day 70.
    • Months. Homocysteine; no trial has defined a weeks-scale course.
    • About six months. Red-cell EPA reaches steady state after 180 days, so the omega-3 index plateaus late.
    • Slowest. hs-CRP did not change significantly across 44 randomized ketogenic trials. A flat CRP at three months is not a failed intervention.

    Documentation and workflow

    The sequence documents cleanly. A metabolic panel, cognitive score and autonomic or balance baseline recorded before dietary counseling sit naturally within the annual wellness visit and chronic care follow-up, and repeats at ten weeks and six months give the chart a dated trajectory rather than a single value. Findings route to the ordering physician; see getting results into the record. The deeper failure is structural: carbohydrate restriction spreads through patient communities faster than medication plans are rewritten, and a regimen dosed for the old diet keeps working against the new one. The full safety evidence, with case reports and declared industry ties, is in the Chapter 10 companion evidence guide; the cognitive trial evidence is in ketogenic therapy in mild cognitive impairment.

    Frequently asked questions

    Which patients most need an autonomic baseline before carbohydrate restriction?

    Patients on two or more antihypertensives, older adults with prior dizziness or falls, and anyone with symptoms suggesting autonomic dysfunction. Sodium and water loss in the first week is predictable; the open question is whether the patient’s regulation can absorb it without symptoms. What the testing characterizes is summarized under autonomic nervous system testing.

    Why is euglycemic ketoacidosis easy to miss?

    SGLT2 inhibitors spill glucose into the urine while insulin is too low to suppress ketone production, so glucose can sit near normal during significant acidosis. Published cases describe patients discharged because marked hyperglycemia was absent, and a home glucose reading does not exclude it. Contact between visits matters most in the first weeks; see chronic care and between-visit monitoring.

    When should the metabolic panel be repeated?

    Fuel markers such as fasting insulin, glucose and HbA1c are informative at about ten weeks, since most of their one-year change had occurred by day 70 in a supervised cohort. Homocysteine, the omega-3 index and hs-CRP need about six months. Scheduling the repeat with the first order keeps it from being skipped; see staffing and workflow.

    Does a cognitive baseline conflict with the USPSTF position on screening?

    No. The USPSTF statement addresses screening asymptomatic adults over 65. A baseline obtained in a patient with a concern, before a deliberate metabolic intervention, serves a different purpose: it is the reference for interpreting later change in that individual. The broader selection logic is described in selection criteria.

    How do these findings support quality reporting?

    Documented metabolic markers, cognitive scores and fall-risk assessments map to quality concepts practices already track, and dated repeats show follow-through on abnormal results. The patient-facing version of this workup is dementia prevention for patients, and measure alignment is outlined in HEDIS and value-based care.

    What are the side effects of a low-carb diet in the first week?

    Sodium and water loss dominate the first week, so dizziness on standing is the side effect most likely to appear early, especially in patients on two or more antihypertensives. Patients on insulin, a sulfonylurea or a meglitinide face hypoglycemia, which Dr. Padda reports seeing within days in his own patients. Patients on an SGLT2 inhibitor face euglycemic ketoacidosis. A baseline recorded before the diet makes each of these visible.

    Who should avoid a low-carb diet?

    The 2025 ADA Standards state that very-low-carbohydrate plans are not currently recommended in pregnancy or lactation, in children, in kidney disease, or in people with or at risk for disordered eating. The diet is contraindicated in a suspected inherited disorder of fat metabolism. Liver, gallbladder or pancreatic disease and moderate or advanced dementia also belong on the flag list, along with every patient whose medications need adjusting first.

    Is a low-carb diet safe if you take diabetes medication?

    Only with a medication plan written before the diet starts. The 2025 ADA Standards call for consistent medical oversight of very-low-carbohydrate eating and recognize that diabetes medications may need adjustment to prevent hypoglycemia. Published practical guides reduce doses at initiation rather than after the first low reading. In a remotely supervised cohort of 262 adults with type 2 diabetes, sulfonylurea use went from 23.7% to 0% in a year under daily glucose review.

    Is a low-carb diet safe for older adults with dementia?

    Stage decides it. In the KDRAFT pilot, 1 of 7 participants with very mild Alzheimer’s withdrew, and all 4 with moderate disease withdrew, each citing caregiver burden. The 2024 ESPEN guideline does not recommend routine ketogenic diets in dementia and treats malnutrition screening as essential. Bioimpedance body composition shows whether the weight an older patient loses is fat or lean mass, which the scale cannot.

    See how the protocol fits your practice

    Learn how Measura’s autonomic, cognitive and metabolic baselines fit a practice workflow, from standing orders to scheduled repeats and results in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • American Diabetes Association Professional Practice Committee. (2025a). 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2025. Diabetes Care, 48(Suppl. 1), S86–S127. https://doi.org/10.2337/dc25-S005
    • Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017). Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes/Metabolism Research and Reviews, 33(8), Article e2924. https://doi.org/10.1002/dmrr.2924
    • Douros, A., Lix, L. M., Fralick, M., Dell’Aniello, S., Shah, B. R., Ronksley, P. E., Tremblay, É., Hu, N., Alessi-Severini, S., Fisher, A., Bugden, S. C., Ernst, P., Filion, K. B., & the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. (2020). Sodium–glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: A multicenter cohort study. Annals of Internal Medicine, 173(6), 417–425. https://doi.org/10.7326/M20-0289
    • DeHaven, J., Sherwin, R., Hendler, R., & Felig, P. (1980). Nitrogen and sodium balance and sympathetic-nervous-system activity in obese subjects treated with a low-calorie protein or mixed diet. The New England Journal of Medicine, 302(9), 477–482. https://doi.org/10.1056/NEJM198002283020901
    • Leslie, W. S., Ali, E., Harris, L., Messow, C. M., Brosnahan, N. T., Thom, G., McCombie, E. L., Barnes, A. C., Sattar, N., Taylor, R., & Lean, M. E. J. (2021). Antihypertensive medication needs and blood pressure control with weight loss in the Diabetes Remission Clinical Trial (DiRECT). Diabetologia, 64(9), 1927–1938. https://doi.org/10.1007/s00125-021-05471-x
    • Taylor, M. K., Sullivan, D. K., Mahnken, J. D., Burns, J. M., & Swerdlow, R. H. (2018). Feasibility and efficacy data from a ketogenic diet intervention in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 4, 28–36. https://doi.org/10.1016/j.trci.2017.11.002
    • Huh, Y., Nam, G. E., Han, K., Jung, J.-H., Kim, B. S., Lee, D., Park, H. J., Yoo, M. Y., Yoon, S. Y., Kang, S. H., Kim, C. K., Kim, S. M., & Park, H. S. (2026). Body mass index levels and changes before and after dementia diagnosis and risk of all-cause mortality: A nationwide cohort study. Alzheimer’s Research & Therapy, 18(1), article 10.1186/s13195–026–02002–x (page not assigned in PubMed record). https://doi.org/10.1186/s13195-026-02002-x
    • Hallberg, S. J., McKenzie, A. L., Williams, P. T., Bhanpuri, N. H., Peters, A. L., Campbell, W. W., Hazbun, T. L., Volk, B. M., McCarter, J. P., Phinney, S. D., & Volek, J. S. (2018). Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year: An open-label, non-randomized, controlled study. Diabetes Therapy, 9(2), 583–612. https://doi.org/10.1007/s13300-018-0373-9
    • Ji, J., Fotros, D., Sohouli, M. H., Velu, P., Fatahi, S., & Liu, Y. (2025). The effect of a ketogenic diet on inflammation-related markers: A systematic review and meta-analysis of randomized controlled trials. Nutrition Reviews, 83(1), 40–58. https://doi.org/10.1093/nutrit/nuad175
    • US Preventive Services Task Force (Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., Landefeld, C. S., Mangione, C. M., Pbert, L., Silverstein, M., Simon, M. A., Tseng, C.-W., & Wong, J. B.). (2020). Screening for cognitive impairment in older adults: US Preventive Services Task Force recommendation statement. JAMA, 323(8), 757–763. https://doi.org/10.1001/jama.2020.0435

    Related reading

  • Dr. Gurpreet Singh Padda beside the title card reading One Correction, Many Diseases: What Ketogenic Therapy Proves, The Starved Brain, Chapter 9

    Ketogenic Diet, Mild Cognitive Impairment and the Screening Workup

    One Correction, Many Diseases: What Ketogenic Therapy Proves | The Starved Brain, Chapter 9

    Ketogenic Diet, Mild Cognitive Impairment and the Screening Workup

    The ketogenic diet produces modest, reproducible cognitive gains in mild cognitive impairment, MMSE up 1.25 points across ten pooled trials with daily function unchanged, but those trials excluded the insulin-resistant patient most panels carry. The screening workup is a metabolic and cognitive baseline before any supervised trial.

    Patients with memory complaints now arrive asking about ketones. The evidence is modest, specific and built on exclusions, and it names the baseline numbers a supervised trial needs.

    Questions that pair the ketogenic diet, mild cognitive impairment and memory now reach primary care before physicians raise the subject, and most of what patients have read is either promotion or dismissal. The evidence reviewed in The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and in its chapter video, One Correction, Many Diseases, supports a narrower position: guideline-level therapy in drug-resistant epilepsy, modest reproducible cognitive effects in MCI and early Alzheimer’s disease, and an unresolved signal in Parkinson’s disease. For the screening physician the useful question is not whether to endorse a diet. It is who warrants a metabolic and cognitive baseline, and what that baseline changes. Measura [Cardiometabolic and Autonomic Health Analysis] provides that measurement layer and does not treat.

    Does a ketogenic diet help mild cognitive impairment? Effect sizes at their true size

    • BENEFIC randomized 122 adults aged 55 and older with MCI to 30 g a day of ketogenic MCT emulsion or calorie-matched placebo for six months; 83 completed. Word recall, verbal fluency, naming and Trail-Making errors improved after adjustment, and the change in blood ketones correlated with cognitive change (r = +0.325 for fluency). Discontinuation was 32%, gastrointestinal adverse events occurred in 74% of drink completers against 40% on placebo, and no Alzheimer’s biomarker moved.
    • Rong 2024 pooled ten randomized trials, 691 participants, 12 to 60 weeks: MMSE +1.25 (95% CI 0.46 to 2.04), ADAS-Cog −3.43, activities of daily living unchanged (P = 0.95). Eight trials used MCT, and the funnel plot suggested publication bias for MMSE.
    • The whole-diet crossover (Phillips 2021) in 26 people with probable Alzheimer’s: daily function +3.13 against a prespecified meaningful difference of 2, quality of life +3.37, cognition unchanged (P = 0.24).

    For context, lecanemab slowed decline by 0.45 points on an 18-point scale over 18 months with imaging edema in 12.6%, and donanemab by 0.70 points over 76 weeks with edema in 24.0%. Scales, durations and constructs differ, so these are not head-to-head comparisons, and improvement is a different quantity from slowed decline. They do set the backdrop for a modest nutritional signal, following a registry record in which 99.6% of Alzheimer’s drug trials registered between 2002 and 2012 failed.

    Who did the ketogenic diet trials exclude?

    BENEFIC excluded uncontrolled diabetes, cardiac, hepatic and renal disease, uncontrolled hypertension and dyslipidemia, and B12 deficiency. The Alzheimer’s diet trial excluded moderate or severe depression, substantial cerebrovascular disease, and abnormal B12, folate or thyroid values. The PET studies establishing preserved ketone uptake selected participants for a similar metabolic phenotype. The insulin-resistant older adult with hepatic steatosis who dominates a primary care panel was, by design, absent.

    Two consequences follow. First, the nutrient hypothesis, that a whole-food ketogenic diet repletes B12, choline and DHA as well as correcting fuel supply, was screened out rather than tested; a trial that excludes deficiency cannot detect a repletion effect. Second, response in the metabolically complex patient is uncertain in both directions. The BENEFIC authors anticipated a reduced response in prediabetic older adults, while the 2026 Washington University trial in prediabetes with fatty liver, holding weight loss at 10% in every arm, found hepatic insulin sensitivity improved two to three times more on the ketogenic diet than on the Mediterranean diet (p < 0.001), with no between-group difference in LDL cholesterol or apoB. That trial is so far reported in abstract. Uncertainty of that shape argues for baseline measurement, not for a blanket recommendation in either direction.

    Does APOE4 status predict response to a ketogenic diet?

    Carrier status is the objection patients raise most, and the data do not run one way. In a Stockholm cohort of 2,157 adults aged 60 and over without dementia at entry, 569 of them carriers, the highest meat-intake quintile carried a dementia subhazard of 0.45 (95% CI 0.21 to 0.95) among carriers, with a non-significant genotype interaction for dementia and a clearer interaction on global cognition. Against that, pooled MCT trials favored non-carriers (SMD 1.87), and an umbrella review found dietary interventions other than the Mediterranean pattern generally ineffective in older carriers, while small exploratory BENEFIC subgroups pointed the other way. The defensible reading is heterogeneity: carriers appear more sensitive to metabolic inputs, and the direction in an individual has to be observed rather than assumed.

    The baseline that makes a supervised trial interpretable

    For a patient with MCI, subjective decline or a strong family history who is considering supervised ketogenic therapy, a defensible pre-intervention set looks like this:

    • Cognitive assessment, because every positive trial reported change on a scored instrument, and an individual needs the same anchor. Pairing it with fall-risk work is covered in cognitive assessment and fall prevention.
    • Laboratory panels with fasting insulin reported as a number, lipids including apoB or particle measures, and a plan for beta-hydroxybutyrate monitoring through the supervising clinician. Across 62 randomized trials in adults, triglycerides fell 19.96 mg/dL while LDL cholesterol rose 8.49 mg/dL; the Parkinson’s pilot saw LDL rise 0.70 mmol/L in eight weeks. The diet trials that separated ran beta-hydroxybutyrate between 0.95 and 1.3 mmol/L, and the 2026 Parkinson’s crossover defined nutritional ketosis as above 0.5 mM.
    • Bioimpedance body composition, since weight fell 2.62 kg in the Alzheimer’s diet trial, and an older adult losing lean mass is a different outcome from one losing visceral fat.

    Dr. Padda’s threshold for concern is a fasting insulin above 10 µIU/mL, stated as his clinic cutoff; the published neighbor is a level above 9.0 that identified 80% of prediabetes in one practice. In 683 older Manhattan adults, hyperinsulinemia carried HR 2.1 for Alzheimer’s disease.

    What safety signals come before ordering a ketogenic diet?

    The Parkinson’s pilot reported transient worsening of tremor or rigidity in 12 of 24 ketogenic patients during weeks one to four. A 2026 case series described nine cases of hypomania or mania within two months of starting a ketogenic diet, seven without prior bipolar history, with no denominator. A bipolar pilot recorded euglycemic ketoacidosis in a participant taking an SGLT2 inhibitor. Diabetes, antihypertensive and cholinesterase-inhibitor regimens were excluded from the MCI trial rather than managed within it. Those are prescriber conversations that precede any dietary counseling, and measurement ordered under standing orders for screening makes the sequence reproducible.

    Documentation and workflow

    A cognitive baseline and metabolic panel fit structures practices already run. The annual wellness visit is a natural home for a documented cognitive score that becomes the comparison point for the next visit, and findings can be recorded against the quality concepts described in MIPS and quality reporting. The system failure is familiar: nutrition is delegated to a handout while visit time goes to prescriptions, and a diet nobody measures cannot be told apart from a diet that failed. Adherence is the other constraint; a modified Atkins pilot found 27 willing patients in two and a half years. A repeat panel at three months tells physician and patient whether the correction is happening at all. Primary studies, methods, sponsorship and limits are laid out in the Chapter 9 companion evidence guide, and the pre-diet safety workup and re-measure schedule continue in low-carb diet safety for physicians.

    Frequently asked questions

    Which patients are reasonable candidates for a baseline before ketogenic therapy?

    Patients with mild cognitive impairment or subjective decline who are considering supervised ketogenic therapy, particularly those with insulin resistance, because the brain trials excluded them and their response cannot be inferred. A strong family history or known APOE4 status adds a reason to observe rather than assume. The broader selection logic is outlined in selection criteria.

    Does an MMSE gain of 1.25 points matter clinically?

    It is a modest pooled effect across ten small trials, mostly MCT supplements, with possible publication bias and no change in daily function. It is not equivalent to slowed decline and should not be set against antibody endpoints. Its value is as evidence that fuel supply is partly responsible, which justifies individual measurement. See interpreting the report.

    Should ketone monitoring be part of the protocol?

    The positive diet trials ran beta-hydroxybutyrate between 0.95 and 1.3 mmol/L, while an arm that stayed below ketosis did not separate. Without a measured level, adherence and exposure are unknown and a null result cannot be interpreted. Monitoring runs through the clinician supervising the diet; Measura supplies the surrounding metabolic and cognitive context, as set out in clinical rationale.

    How should baseline results reach the chart?

    Findings are reported to the ordering physician and belong alongside the cognitive score in the record, so a three-month repeat is compared against the same fields rather than reconstructed from memory. Practical options for structured results are covered in getting results into the record.

    Is ketogenic therapy reasonable in Parkinson’s disease?

    One randomized pilot in 47 patients found larger improvement in non-motor symptoms on a ketogenic diet than on a low-fat diet, with no motor difference, while a systematic review judged the broader human evidence insufficient for most outcomes. That supports a supervised trial in an individual patient, not a general recommendation. The patient-facing view is keto diet and Alzheimer’s for patients.

    Does a ketogenic diet improve cognition in mild cognitive impairment?

    Modestly, yes. In BENEFIC, 122 adults with MCI randomized to a ketogenic MCT drink for six months improved word recall, verbal fluency, naming and Trail-Making errors, and the change in blood ketones tracked the change in cognition. Pooled across ten trials, MMSE rose 1.25 points with daily function unchanged. No Alzheimer’s biomarker moved.

    How well do older patients tolerate ketogenic MCT drinks?

    Tolerance is the practical limit. In BENEFIC, discontinuation was 32%, only 83 of 122 randomized participants completed, and gastrointestinal adverse events occurred in 74% of drink completers against 40% on placebo. Whole diets carry their own adherence problem: a modified Atkins pilot found 27 willing patients in two and a half years. A repeat panel at three months shows whether the correction is happening at all.

    Is a whole-food ketogenic diet different from MCT supplements in the trials?

    Yes. Eight of the ten pooled trials used MCT, and the whole-diet crossover in 26 people with probable Alzheimer’s improved daily function and quality of life but not cognition. The nutrient hypothesis, that a whole-food diet also repletes B12, choline and DHA, was screened out rather than tested, because trials that exclude deficiency cannot detect a repletion effect.

    See how the protocol fits your practice

    Learn how Measura’s cognitive, metabolic and body-composition testing fits a primary care or specialty workflow, from standing orders to results in the chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Fortier, M., Castellano, C.-A., St-Pierre, V., Myette-Côté, É., Langlois, F., Roy, M., Morin, M.-C., Bocti, C., Fulop, T., Godin, J.-P., Delannoy, C., Cuenoud, B., & Cunnane, S. C. (2021). A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimer’s & Dementia, 17(3), 543–552. https://doi.org/10.1002/alz.12206
    • Rong, L., Peng, Y., Shen, Q., Chen, K., Fang, B., & Li, W. (2024). Effects of ketogenic diet on cognitive function of patients with Alzheimer’s disease: A systematic review and meta-analysis. The Journal of Nutrition, Health and Aging, 28(8), 100306. https://doi.org/10.1016/j.jnha.2024.100306
    • Phillips, M. C. L., Deprez, L. M., Mortimer, G. M. N., Murtagh, D. K. J., McCoy, S., Mylchreest, R., Gilbertson, L. J., Clark, K. M., Simpson, P. V., McManus, E. J., Oh, J.-E., Yadavaraj, S., King, V. M., Pillai, A., Sequeira, B., Rodgers, B., Wiltshire, C., Tanner, S., & Tisch, S. (2021). Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimer’s Research & Therapy, 13(1), 51. https://doi.org/10.1186/s13195-021-00783-x
    • van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L. D., & Iwatsubo, T. (2023). Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
    • Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., Collins, E. C., Solomon, P., Salloway, S., Apostolova, L. G., Hansson, O., Ritchie, C., Brooks, D. A., Mintun, M., Skovronsky, D. M., & TRAILBLAZER-ALZ 2 Investigators. (2023). Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA, 330(6), 512–527. https://doi.org/10.1001/jama.2023.13239
    • Cummings, J. L., Morstorf, T., & Zhong, K. (2014). Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures. Alzheimer’s Research & Therapy, 6(4), 37. https://doi.org/10.1186/alzrt269
    • Norgren, J., Carballo-Casla, A., Grande, G., Börjesson-Hanson, A., Xu, H., Eriksdotter, M., Laukka, E. J., & Garcia-Ptacek, S. (2026). Meat consumption and cognitive health by APOE genotype. JAMA Network Open, 9(3), Article e266489. https://doi.org/10.1001/jamanetworkopen.2026.6489
    • Sun, L., Ye, K. X., Wong, H. L. K., Wang, L., Lim, S. L., Chao, Y. X., Zhang, C., Yap, K. Z., & Feng, L. (2023). The effects of medium chain triglyceride for Alzheimer’s disease related cognitive impairment: A systematic review and meta-analysis. Journal of Alzheimer’s Disease, 94(2), 441–456. https://doi.org/10.3233/JAD-230406
    • Petersen, M. C., Smith, G. I., Farabi, S. S., Palacios, H. H., Shankaran, M., Hellerstein, M. K., Patterson, B. W., & Klein, S. (2026). Effect of diet macronutrient content on the cardiometabolic response to weight loss: A randomized clinical trial. Cell Metabolism. Advance online publication. https://doi.org/10.1016/j.cmet.2026.07.020
    • Chang, C., Liu, Y., Rohani, P., Khodadadi, N., Prabahar, K., & Sohouli, M. H. (2026). The impact of the ketogenic diet on the lipid profile in adults: A comprehensive review and meta-regression analysis of randomized controlled trials. Endocrine Practice, 32(5), 819–828. https://doi.org/10.1016/j.eprac.2026.01.009

    Related reading

  • Dr. Gurpreet Singh Padda in a lab coat beside the title card reading The Gum Bacterium in 96% of Alzheimer's Brains, The Starved Brain, Chapter 8

    Periodontal Disease and Dementia: A Screening Workflow

    The Gum Bacterium in 96% of Alzheimer's Brains | The Starved Brain, Chapter 8

    Periodontal Disease and Dementia: A Screening Workflow

    The oral exposure tied to dementia risk is severe periodontitis, and it lives in a dental chart that most medical records never import. Closing that gap is a workflow decision before it is a research question.

    The periodontal disease dementia literature has matured past the point where it can be dismissed, and not to the point where it supports an intervention claim. Dr. Padda’s companion video for the book, The Gum Bacterium in 96% of Alzheimer’s Brains, reviews the argument from The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, including a correction of a claim his own side repeats. For a practice, the usable output is narrower than the headline: which patients carry the exposure, what documentation connects it to the cognitive and metabolic workup, and what a finding changes. Measura [Cardiometabolic and Autonomic Health Analysis] performs no dental, salivary or microbial testing. Its role here is the metabolic, vascular and cognitive measurement in the same patient.

    Is periodontal disease a risk factor for dementia?

    Five syntheses from independent teams land in a narrow band. Nadim pooled cohorts at RR 1.18 (1.06–1.31). Larvin reported dementia RR 1.22 and cognitive decline RR 1.33. Dibello reproduced dementia RR 1.22 and ran depression as a negative control, which came back null at RR 1.07 (0.95–1.21). The 2025 umbrella review gives cohorts RR 1.26 (1.20–1.32), low to moderate certainty by GRADE. Measurement quality points the right way: self-reported periodontitis produced weaker estimates than clinically examined disease, the pattern expected from a real exposure measured imperfectly.

    The clinically decisive finding is severity. Pooling 13 case-control and 11 cohort studies, severe periodontitis carried OR 2.85 (2.16–3.74), while less-than-moderate disease carried OR 0.94 (0.64–1.40). Screening should therefore ask for staging, not a yes or no. The largest single estimate, HR 1.79 in 56,018 Taiwanese adults from claims data, partly measures who seeks care: people who see a dentist also see physicians.

    Can periodontal bacteria reach the brain? Mechanism, with provenance

    Dominy and colleagues found arginine-gingipain B in 51 of 53 Alzheimer’s temporal cortex samples, and lysine-gingipain in 91%, with RgpB tracking tau at r = 0.674 and ubiquitin at 0.786. The control column is less often quoted: RgpB in 18 of 46 non-demented samples, Kgp in 52%, and the bacterial gene in five of six control brains by qPCR. Twelve of twenty-five authors were employees of the company developing the inhibitor, and independent replication of the brain immunohistochemistry has not appeared. Ilievski’s wild-type mouse study, 10 exposed and 10 controls over 22 weeks, showed that oral inoculation can produce hippocampal inflammation, Aβ1–42 and phospho-tau. It reported pathology, not cognition. And a prospective human serology study of 158 cognitively intact adults found baseline antibodies in future cases to Fusobacterium nucleatum and Prevotella intermedia, not P. gingivalis. A 2026 review still judges that confounding, reverse causation and dental-care access preclude causal inference.

    Does targeting P. gingivalis slow Alzheimer’s? GAIN and the genetic nulls

    GAIN randomized 643 patients with mild-to-moderate Alzheimer’s at 93 sites to two doses of atuzaginstat or placebo for 48 weeks and missed both co-primary endpoints, ADAS-Cog11 and ADCS-ADL. Liver enzymes above three times the upper limit of normal occurred in 2% on placebo, 7% at 40 mg and 15% at 80 mg; FDA holds followed and the program closed in August 2022. In the pre-specified subgroup of 242 with salivary P. gingivalis DNA, ADAS-Cog11 decline was 57% slower at the higher dose, with no functional effect. The successor enrolls only organism-positive patients and reports in 2029. Two Mendelian randomization studies are null or unstable: Sun found OR 1.10 on one instrument set and 0.97 on a second, and Hu found no causal relationship.

    The exclusion that matters to a primary care or endocrine panel: GAIN excluded HbA1c above 8 and BMI of 38 or more. The insulin-resistant, centrally obese patient whose inflammatory burden is highest never entered the one randomized test. A 48-week trial in established dementia may also be testing a decades-long exposure at the wrong end. That is a criticism of the design, not evidence for the drug.

    Which patients should be screened for periodontal disease, and what does a finding change?

    Ask about periodontal status, and request staging, in patients undergoing cognitive assessment, in patients with diabetes or insulin resistance, and in older adults with known severe disease or heavy tooth loss. The CDC full-mouth survey of 10,683 dentate adults found periodontitis in 42% of those 30 to 79 and severe disease in 7.8%, and partial-mouth protocols can underestimate prevalence by more than 50%, so a full-mouth chart with periodontal inflamed surface area is the document worth requesting. The structural driver is that the dental and medical records sit in different buildings, maintained by different systems, and neither side is prompted to ask for the other’s chart (selection criteria).

    A finding of severe periodontitis changes management in concrete ways. It supports referral for periodontal treatment on its own merits: across 30 studies with 2,443 analyzed participants with diabetes, subgingival instrumentation lowered HbA1c by 0.43% at three to four months, moderate certainty, though 33 of 35 studies carried high or unclear risk of bias. It changes lab timing: in 120 patients with severe periodontitis, intensive treatment lowered flow-mediated dilatation and raised CRP and IL-6 at 24 hours, then improved dilatation by 180 days, so an hs-CRP drawn the day after treatment reads the procedure. And it argues for a cognitive assessment baseline, repeatable on the same instrument, rather than waiting for a complaint.

    Where Measura measurement fits

    Measura cannot stage the gums or detect the organism. It measures the terrain around the exposure. Laboratory panels put HbA1c, fasting insulin and inflammatory markers next to the dental chart; the Puerto Rico cohort of 1,206 overweight adults found that progression of attachment loss, IRR 1.25, rather than baseline periodontitis, tracked incident dysglycemia, so trending both charts together is more informative than either snapshot. Arterial stiffness and endothelial function testing covers the vascular domain in which the Tonetti trial documented systemic effects, without claiming to replicate its method. Bioimpedance body composition characterizes the adiposity that excluded patients from GAIN. Pair the cognitive baseline with fall-risk work where the patient population overlaps (cognitive assessment and fall prevention).

    Documentation and workflow

    Add periodontal staging to the history captured at the annual wellness visit, with the date of the dental chart it came from (annual wellness visit integration). Build the request for the dental chart into standing orders for patients meeting criteria, so it happens without depending on memory at the point of care (standing orders that make screening reproducible). A patient version of this material is written separately (the patient article on gum disease and dementia), the referenced evidence sits in the book companion (Chapter 8 companion), and the preceding physician article covers the metabolic inflammation that this oral source adds to (metaflammation screening).

    Frequently asked questions

    Should periodontal status be part of a cognitive workup?

    Yes, as history and staging rather than as a diagnostic claim. The association is modest overall and concentrated in severe disease, and treatment is indicated independently of any brain effect. Recording stage and chart date costs one question and one records request, and it keeps a treatable inflammatory source from being missed in patients already under cognitive evaluation. Structuring that evaluation is covered in interpreting the report.

    Is salivary P. gingivalis testing ready for clinical use?

    Not on current evidence. Salivary DNA defined a pre-specified subgroup inside a failed trial, and the successor trial using it as an entry criterion does not report until 2029. It is a research stratifier. Measura does not offer it or any microbial test. The practical signal available now is periodontal staging from a full-mouth dental examination. The measurement rationale Measura does support is laid out in clinical rationale.

    Does vitamin D belong in this workup?

    It belongs for reasons the mouse models cannot test. The vitamin D response element driving cathelicidin, LL-37, sits in a primate-specific genetic element absent in mice, rats and dogs, so every animal study here is blind to that limb. No source sets a 25-hydroxyvitamin D level for adequate LL-37 production, and no LL-37 assay is validated clinically. Order it as part of the metabolic panel, not as a periodontal marker. See specialty applications.

    How should inflammatory markers be timed around periodontal therapy?

    Avoid the first days after intensive treatment. In the randomized trial of 120 patients with severe periodontitis, CRP, IL-6 and von Willebrand factor rose at 24 hours while flow-mediated dilatation fell, and vascular function improved by 180 days. A baseline before treatment and a repeat months later is interpretable; a draw the morning after is not. Scheduling repeat measurement is addressed in chronic care and between-visit monitoring.

    How do dental findings get into the medical record?

    Usually they do not, which is the problem. Request the full-mouth periodontal chart with bleeding on probing and inflamed surface area, and file the staging and date in a discrete history field rather than a scanned attachment, so it can be retrieved beside HbA1c and cognitive scores at the next visit. Options for structured results are described in getting results into the record.

    Which dental disease is linked to Alzheimer’s disease and dementia?

    Periodontitis, and specifically severe periodontitis. Pooling 13 case-control and 11 cohort studies, severe disease carried OR 2.85 (2.16–3.74), while less-than-moderate disease carried OR 0.94 (0.64–1.40). Pooled cohort estimates across all severities run from RR 1.18 to 1.26. That gradient is why a periodontal history should record stage from a full-mouth chart rather than a yes or no answer.

    Does periodontal disease cause dementia?

    Causation is not established. Five independent syntheses agree on a modest association, and clinically examined disease gives stronger estimates than self-report. But GAIN missed both co-primary endpoints, two Mendelian randomization studies were null or unstable, and a 2026 review still judges that confounding, reverse causation and dental-care access preclude causal inference. Periodontal treatment is indicated on its own merits regardless.

    How common is periodontitis in adults?

    In the CDC full-mouth survey of 10,683 dentate adults aged 30 to 79, 42% had periodontitis and 7.8% had severe disease. Partial-mouth protocols can underestimate prevalence by more than 50%, so a partial exam in the chart can miss much of it. The document worth requesting is a full-mouth chart with periodontal inflamed surface area.

    See how the Measura protocol fits your practice

    Learn how cognitive, metabolic and vascular measurements can sit beside periodontal history in your screening workflow, standing orders and wellness visit documentation.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Qadir, B. H., Mahmood, M. K., Amin, Y. M. M., Kurda, H. A., Rasheed, T. A., Noori, A. H., Noori, Z. F., Abdulghafor, M. A., Fadhil, H. N. M., Fatih, M. T., Tardivo, D., Tassery, H., & Lan, R. (2025). Periodontitis and tooth loss are associated with higher risks of cognitive disorders: A systematic umbrella meta-analysis. Clinical and Experimental Dental Research, 11(6), Article e70240. https://doi.org/10.1002/cre2.70240
    • Kim, D.-H., & Han, G.-S. (2025). Periodontitis as a risk factor for dementia: A systematic review and meta-analysis. The Journal of Evidence-Based Dental Practice, 25(2), Article 102094. https://doi.org/10.1016/j.jebdp.2025.102094
    • Larvin, H., Gao, C., Kang, J., Aggarwal, V. R., Pavitt, S., & Wu, J. (2023). The impact of study factors in the association of periodontal disease and cognitive disorders: Systematic review and meta-analysis. Age and Ageing, 52(2), Article afad015. https://doi.org/10.1093/ageing/afad015
    • Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., Holsinger, L. J., Arastu-Kapur, S., Kaba, S., Lee, A., Ryder, M. I., Potempa, B., Mydel, P., Hellvard, A., Adamowicz, K., … Potempa, J. (2019). Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science Advances, 5(1), Article eaau3333. https://doi.org/10.1126/sciadv.aau3333
    • Sparks Stein, P., Steffen, M. J., Smith, C., Jicha, G., Ebersole, J. L., Abner, E., & Dawson, D. (2012). Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimer’s & Dementia, 8(3), 196–203. https://doi.org/10.1016/j.jalz.2011.04.006
    • Sun, Y.-Q., Richmond, R. C., Chen, Y., & Mai, X.-M. (2020). Mixed evidence for the relationship between periodontitis and Alzheimer’s disease: A bidirectional Mendelian randomization study. PLoS ONE, 15(1), Article e0228206. https://doi.org/10.1371/journal.pone.0228206
    • Eke, P. I., Thornton-Evans, G. O., Wei, L., Borgnakke, W. S., Dye, B. A., & Genco, R. J. (2018). Periodontitis in US adults: National Health and Nutrition Examination Survey 2009–2014. Journal of the American Dental Association, 149(7), 576–588.e6. https://doi.org/10.1016/j.adaj.2018.04.023
    • Simpson, T. C., Clarkson, J. E., Worthington, H. V., MacDonald, L., Weldon, J. C., Needleman, I., Iheozor-Ejiofor, Z., Wild, S. H., Qureshi, A., Walker, A., Patel, V. A., Boyers, D., & Twigg, J. (2022). Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Cochrane Database of Systematic Reviews, 4(4), Article CD004714. https://doi.org/10.1002/14651858.CD004714.pub4
    • Tonetti, M. S., D’Aiuto, F., Nibali, L., Donald, A., Storry, C., Parkar, M., Suvan, J., Hingorani, A. D., Vallance, P., & Deanfield, J. (2007). Treatment of periodontitis and endothelial function. New England Journal of Medicine, 356(9), 911–920. https://doi.org/10.1056/NEJMoa063186
    • Joshipura, K. J., Muñoz-Torres, F. J., Dye, B. A., Leroux, B. G., Ramírez-Vick, M., & Pérez, C. M. (2018). Longitudinal association between periodontitis and development of diabetes. Diabetes Research and Clinical Practice, 141, 284–293. https://doi.org/10.1016/j.diabres.2018.04.028

    Related reading

  • Dr. Gurpreet Singh Padda in a lab coat beside the title card reading Fructose Turns the Famine Signal On, The Starved Brain, Chapter 7

    Metaflammation Screening: What the Standard Panel Misses

    Fructose Turns the Famine Signal On | The Starved Brain, Chapter 7

    Metaflammation Screening: What the Standard Panel Misses

    Metaflammation screening in primary care measures what the standard panel misses: fasting glucose and HbA1c flag only the patient whose compensation has already failed. Waist circumference, body composition, measured resting energy expenditure, fasting insulin, uric acid, hs-CRP and oxidized LDL fill the gap, starting with patients who carry central adiposity at any BMI.

    Chronic metabolic inflammation is clinically silent, and the panel most practices order was never designed to find it. The practical questions are who to measure, with what, and what a result changes.

    Metaflammation, Hotamisligil’s term for chronic inflammation driven by metabolic excess, has a screening problem built into its definition: it produces no findings on examination and no complaint at the front desk. The chapter video, Fructose Turns the Famine Signal On, lays out the case from The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP that fructose load, visceral fat and diet-related endotoxin keep that inflammation running, with consequences reaching the brain. Measura [Cardiometabolic and Autonomic Health Analysis] is a testing protocol, not a treatment service, so the relevant question for a practice is operational. Which patients should be measured, which measurements add information the routine panel does not, and what does a result change?

    The evidence tier, stated once

    The fructose argument is a hypothesis. Johnson’s 2020 paper reports no trial and no new cohort, and four of its eight authors declared equity in a company developing inhibitors of fructose metabolism. The human data underneath it come from liver, not brain: in 25 obese adults with type 2 diabetes studied by phosphorus spectroscopy, those eating 15 g of fructose a day or more showed a greater fall in hepatic ATP, and those with uric acid at or above 5.5 mg/dL reached a lower nadir. The brain chain is thinner still. Two links are human: systemic inflammatory events in 222 community patients with Alzheimer’s disease meant 3.5 ADAS-Cog points lost over six months against 1.6, and synapse loss tracks cognition in small autopsy series. The middle, metabolic excess priming microglia that then strip synapses, is mouse work, and the human imaging is split: HOMA-IR tracked cortical TSPO binding in 57 unimpaired elders, while 12 BMI-discordant identical twin pairs showed no excess in the heavier twin. That tier does not argue against measuring. It argues against promising what a measurement predicts.

    What does a standard metabolic panel miss?

    Fasting glucose and HbA1c identify the patient whose compensation has already failed. They say nothing about fat distribution, lean mass, resting energy expenditure or inflammatory tone. The more interesting gap is in data already on the chart. Across 23 cohorts and 947,020 participants, a higher neutrophil-to-lymphocyte ratio predicted incident dementia, HR 1.24 (1.15–1.34), with heterogeneity high at I² of 95%. In 161,968 UK Biobank adults, the neutrophil count carried HR 1.08 while the linear CRP hazard sat at 0.95. Cell counts associate with dementia more consistently than CRP does, and a CBC is drawn at nearly every visit for some other reason. Reverse causation is excluded by none of these cohorts, so the ratio is a flag for a closer look, not a result to act on alone.

    High-sensitivity CRP still has a place, read on the scale it was built for: the AHA/CDC bands of under 1 mg/L, 1 to 3 and above 3 are cardiovascular risk tertiles, and a value above 10 calls for a repeat and a search for infection. Pooled data put high CRP ahead of conversion to dementia, HR 1.473, without predicting decline on cognitive tests.

    Who should be screened for metaflammation?

    The selection logic follows the mechanism rather than the diagnosis list. Central adiposity at any BMI qualifies, because waist circumference was associated with mortality within every BMI band from 20 to 50 kg/m², rising 17% in men and 13% in women per 5 cm at a given BMI. So does the patient with normal glucose but a family history, a rising waist or an elevated uric acid, which reads fructose load and is not a validated dementia marker in either direction. Cognitive complaints in a patient carrying that metabolic picture belong on the list too. There is a structural driver worth naming: added sugars supply roughly 15% of energy in the U.S. food supply, and up to 20% or more in some groups, so exposure is set by what is on the shelf, not by a patient’s individual choices. And one non-obvious point on evidence: the fifteen randomized trials that cleared linoleic acid of raising inflammatory markers enrolled healthy people. None enrolled the insulin-resistant patient most practices are trying to screen. The criteria page sets this out in operational form (selection criteria).

    Which tests measure metaflammation?

    Bioimpedance body composition separates fat from lean mass, the distinction BMI erases and the one that matters when visceral fat is the IL-6 source: in 25 extremely obese adults sampled during bypass surgery, portal IL-6 ran about 50% above arterial levels and correlated with CRP. Indirect calorimetry replaces a predicted resting energy expenditure with a measured one. Laboratory panels carry the chemistry: fasting insulin reported on its own, uric acid, hs-CRP, and oxidized LDL with the omega-6 to omega-3 ratio. In CARDIA, among 1,889 adults without metabolic syndrome at baseline, the top quintile of oxidized LDL carried OR 3.5 (1.9–6.6) for developing it within five years, and LDL cholesterol predicted nothing once oxidized LDL entered the model. Assays differ in antibodies and units, so values from different methods cannot be compared directly; pick one method and trend it.

    Where the metabolic picture is abnormal and cognition is part of the concern, a cognitive assessment gives a documented baseline. That pairing also feeds fall prevention, since cognitive and balance workups share a patient population and a visit structure (cognitive assessment and fall prevention).

    What a finding changes

    Measura does not diagnose on its own, and results return to the ordering physician. What a finding changes is the specificity of the conversation. A patient told the A1C is fine hears permission; a patient shown visceral fat, a measured resting energy expenditure and an oxidized LDL in the top of its assay’s range hears a problem with coordinates. It changes follow-up: a defined interval to repeat the same measurements on the same method, so dietary change aimed at added sugar and processed food can be checked against numbers rather than weight alone. It also changes how a CRP above 10 is handled, as a repeat and an infection search, not as metabolic inflammation. None of it requires a medication decision to be useful.

    Documentation and workflow

    Record waist circumference as a vital sign next to BMI. Place the cognitive baseline in the annual wellness visit note where it can be compared year over year, and let standing orders define eligibility so screening does not depend on who had time that afternoon (standing orders for screening). Structured results that land in discrete fields support MIPS and HEDIS documentation far better than scanned reports (MIPS and quality reporting). The patient-facing version of this material is written separately (the patient article on sugar and inflammation), the full referenced evidence sits in the book companion (Chapter 7 companion), and the next physician article takes the same inflammatory argument into periodontal disease (periodontal disease and dementia).

    Frequently asked questions

    Is hs-CRP a reasonable proxy for metaflammation?

    Partly. CRP is the hepatic footprint of IL-6, including IL-6 from the visceral depot, so it reflects some of the load. Its validated bands are cardiovascular. For brain outcomes it is inconsistent: pooled data tie high CRP to dementia conversion, while midlife CRP in 12,336 ARIC participants predicted only a small decline over 20 years. Read it with body composition and cell counts, not alone. Guidance on reading the combined report is in interpreting the report.

    Should oxidized LDL replace LDL cholesterol in screening?

    It adds rather than replaces. In CARDIA it predicted incident metabolic syndrome independent of LDL cholesterol, and in 3,987 non-diabetic PESA adults the top quartile carried OR 2.57 after adjustment for waist and HOMA-IR, though that analysis was cross-sectional. The limitation is analytic: no shared reference range exists across assays. Use one laboratory method consistently and interpret trend. The broader case is in clinical rationale.

    Is uric acid worth ordering if it is not a dementia marker?

    Yes, for what it does measure. Serum urate climbs by 0.3 to 2.0 mg/dL in the first hour after a fructose dose, and in the liver spectroscopy study patients at or above 5.5 mg/dL had the deeper energy fall. For dementia the cohorts point both ways and Mendelian randomization was null. Treat it as a fructose-load signal in the metabolic workup. Examples of where it sits in different practices are in specialty applications.

    How often should these measurements be repeated?

    Often enough to see whether management moved them, and always on the same method, since assay changes can masquerade as clinical change. Body composition and resting energy expenditure respond on a slower timescale than a single inflammatory marker, which can swing with an intercurrent infection. Build the interval into the order set rather than leaving it to recall. A general framework is in how often to repeat cardiometabolic testing.

    How do results reach the chart in usable form?

    The value of a baseline depends on retrieving it a year later, which scanned PDFs make difficult. Discrete results mapped to the record let waist, body composition, laboratory values and cognitive scores be trended alongside the problem list and pulled into quality documentation. Options for integration are described in getting results into the record.

    What is metaflammation?

    Metaflammation is Hotamisligil’s term for chronic inflammation driven by metabolic excess. It is low-grade, runs through the whole body and produces no findings on examination and no complaint at the front desk. The case laid out in The Starved Brain is that fructose load, visceral fat and diet-related endotoxin keep it running, with consequences reaching the brain. That silence is why it has to be measured.

    What are the symptoms of metabolic inflammation?

    Usually none a patient reports. Metaflammation is clinically silent, and fasting glucose and HbA1c stay normal until compensation has already failed. What shows it is measurement: a waist circumference out of proportion to BMI, the fat and lean split on body composition, a measured resting energy expenditure, fasting insulin, uric acid, hs-CRP and oxidized LDL, read together and trended on the same method.

    Does a normal A1C rule out metaflammation?

    No. Fasting glucose and HbA1c identify the patient whose compensation has already failed. They say nothing about fat distribution, lean mass, resting energy expenditure or inflammatory tone. A patient told the A1C is fine hears permission; a patient shown visceral fat, a measured resting energy expenditure and an oxidized LDL near the top of its range hears a problem with coordinates.

    See how the Measura protocol fits your practice

    Learn how metabolic, body composition and cognitive measurements are ordered, reported and documented within an existing primary care or specialty workflow.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Johnson, R. J., Gomez-Pinilla, F., Nagel, M., Nakagawa, T., Rodriguez-Iturbe, B., Sanchez-Lozada, L. G., Tolan, D. R., & Lanaspa, M. A. (2020). Cerebral fructose metabolism as a potential mechanism driving Alzheimer’s disease. Frontiers in Aging Neuroscience, 12, Article 560865. https://doi.org/10.3389/fnagi.2020.560865
    • Abdelmalek, M. F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E. W., Balasubramanyam, A., Bantle, J. P., Johnson, R. J., Diehl, A. M., Clark, J. M., & the Fatty Liver Subgroup of the Look AHEAD Research Group (2012). Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology, 56(3), 952–960. https://doi.org/10.1002/hep.25741
    • Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009). Systemic inflammation and disease progression in Alzheimer disease. Neurology, 73(10), 768–774. https://doi.org/10.1212/WNL.0b013e3181b6bb95
    • Toubasi, A. A., & Al-Sayegh, T. N. (2026). Peripheral immune markers in dementia: A systematic review and meta-analysis of risk, severity, and pathological correlates. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 12(2), e70270. https://doi.org/10.1002/trc2.70270
    • Zhong, X., Qiang, Y., Wang, L., Zhang, Y., Li, J., Feng, J., Cheng, W., Tan, L., & Yu, J. (2023). Peripheral immunity and risk of incident brain disorders: a prospective cohort study of 161,968 participants. Translational Psychiatry, 13(1), 382. https://doi.org/10.1038/s41398-023-02683-0
    • Ross, R., Neeland, I. J., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., Cuevas, A., Hu, F. B., Griffin, B. A., Zambon, A., Barter, P., Fruchart, J.-C., Eckel, R. H., Matsuzawa, Y., & Després, J.-P. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology, 16(3), 177–189. https://doi.org/10.1038/s41574-019-0310-7
    • Holvoet, P., Lee, D.-H., Steffes, M., Gross, M., & Jacobs, D. R. (2008). Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA, 299(19), 2287–2293. https://doi.org/10.1001/jama.299.19.2287
    • Ekblad, L. L., Tuisku, J., Koivumäki, M., Helin, S., Rinne, J. O., & Snellman, A. (2023). Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. Journal of Cerebral Blood Flow and Metabolism, 43(9), 1588–1600. https://doi.org/10.1177/0271678X231172519
    • Fontana, L., Eagon, J. C., Trujillo, M. E., Scherer, P. E., & Klein, S. (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56(4), 1010–1013. https://doi.org/10.2337/db06-1656
    • Pearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., Rifai, N., Smith, S. C., Taubert, K., Tracy, R. P., & Vinicor, F. (2003). Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107(3), 499–511. https://doi.org/10.1161/01.CIR.0000052939.59093.45

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 6 title card of The Starved Brain reading Two Windows That Never Reopen.

    B Vitamins in Mild Cognitive Impairment: Measure Before It Is Late

    Two Windows That Never Reopen | The Starved Brain, Chapter 6

    B Vitamins in Mild Cognitive Impairment: Measure Before It Is Late

    Test B12 status in mild cognitive impairment before reaching for B vitamins: in VITACOG, high-dose B vitamins slowed brain atrophy most in people whose homocysteine was high at entry. In anyone over 60, serum B12 goes on the order with methylmalonic acid or holotranscobalamin.

    Nearly the same B-vitamin doses slowed brain atrophy in mild cognitive impairment and did nothing in established Alzheimer’s disease. The variable was not the capsule. It was who was depleted, and when.

    The chapter video, Two Windows That Never Reopen, frames B12 across two irreversible windows, the first thousand days and the last. For primary care, geriatrics and neurology-adjacent practice, the clinically useful half is the second. On B vitamins, mild cognitive impairment and established Alzheimer’s disease give opposite trial answers with nearly the same capsules, and the difference is who was enrolled and when. That is a screening argument before it is a treatment argument.

    Do B vitamins help mild cognitive impairment or Alzheimer’s?

    VITACOG randomized 271 people over 70 with mild cognitive impairment to two years of high-dose B vitamins or placebo; 168 completed paired MRI. Whole-brain atrophy ran 0.76% a year on treatment versus 1.08% on placebo (P = 0.001), and above a baseline homocysteine of 13 µmol/L it was 53% lower. A later analysis reported a cognitive benefit in participants whose homocysteine was high at entry.

    The Alzheimer’s disease trial ran the other direction. It randomized 409 people with mild to moderate disease, MMSE 14–26, to folate 5 mg, B6 25 mg and B12 1 mg or placebo for 18 months. Homocysteine fell 2.42 versus 0.86 µmol/L. The ADAS-cog worsened 0.401 points a month on vitamins and 0.372 on placebo (P = .52), and depression was reported in 28% on vitamins against 18%.

    Two readings fit, and the trial cannot separate them. Too late: the tissue was already lost. Wrong patients: everyone entered with normal folate, B12 and homocysteine, the subgroup VITACOG suggests does not respond. Both readings point to the same clinical move. A struggling neuron can be protected, a lost one cannot be rebuilt, and a patient who is not depleted cannot be repleted. Status has to be measured while the window is open, and treatment follows the measurement rather than the diagnosis.

    Why do older adults become low in B12?

    The common teaching that aging stomachs stop making acid does not hold up. Among 248 independently living older adults, basal gastric contents were acidic in 84%, and the authors noted that nearly 90% could acidify. The deficit concentrates in a subgroup: 31.5% of 359 adults aged 60 to 99 had atrophic gastritis by pepsinogen ratio, with low serum B12 rising stepwise with severity. Food-cobalamin malabsorption accounts for more than 60% of deficiency in older adults and pernicious anemia for 15–20%. After 60, roughly 6% are deficient by plasma B12 and closer to 20% are marginal.

    Serum values understate the problem. In 548 Framingham survivors, methylmalonic acid was markedly raised in 11.3%, and the authors estimated metabolic deficiency at 12% or more, many with normal serum concentrations. The practice position is not to order serum B12 alone in anyone over 60; methylmalonic acid or holotranscobalamin goes on the same order.

    Which medications lower B12 in older patients?

    Acid suppression has a modest but real signal. In Kaiser Permanente data, two or more years of proton pump inhibitor supply carried OR 1.65, H2 blockers alone OR 1.25, and more than 1.5 pills a day OR 1.95, a dose gradient. Pooled data are less certain: one called its pooled OR too low to imply a clear association, and a 2025 meta-analysis of six studies found no difference in serum B12. The average effect is small, but an individual patient with atrophic gastritis is not an average.

    The metformin question is settled by randomization. The Diabetes Prevention Program assigned 1,073 people to metformin and 1,082 to placebo. At five years, B12 at or below 203 pg/mL occurred in 4.3% versus 2.3%, low-plus-borderline in 19.1% versus 9.5%, and each year of use carried OR 1.13. Pooled meta-analytic odds came to 2.45 across 29 studies and 2.95 across 17 later studies in type 2 diabetes.

    Intake, protein and the muscle compartment

    Supply falls on the intake side too. Appetite declines, meat is often dropped first for dental reasons, the effort of cooking for one, or longstanding advice to limit red meat, and the anorexia of aging resists late correction once weight loss is established. Social isolation is a nutritional exposure in this population, not a footnote to it.

    Demand moves the other way. PROT-AGE recommends at least 1.0–1.2 g/kg/day of protein for healthy adults over 65 and 1.2–1.5 g/kg/day in acute or chronic disease, excepting severe kidney disease with eGFR below 30, because older muscle shows declining anabolic response. Sarcopenia is defined as muscle failure that accrues across a lifetime. Chronic low-grade inflammation rises with age, and the same machinery driven by overnutrition is metaflammation, which is why the overfed, insulin-resistant adult runs this program early. Bioimpedance body composition quantifies the lean and fat compartments that weight and BMI blur together.

    Who to test and what to pair it with

    Measura [Cardiometabolic and Autonomic Health Analysis] is a measurement layer that reports to the ordering physician and leaves management with that physician. For this population the useful set is compact: laboratory panels specified to include methylmalonic acid or holotranscobalamin, homocysteine and folate; a cognitive assessment to document a baseline while the patient is still in the “normal for age” zone; and, because sarcopenia and cognitive change travel with falls, vestibular and balance testing as part of fall-risk work. The pairing logic is set out in cognitive assessment and fall prevention.

    One gap is worth naming plainly. VITACOG had four participants with diabetes, so the insulin-resistant patient is effectively missing from the trial that worked. An absence from a trial is a blank, not a finding, and the blank is filled with a measurement rather than an assumption. The first window, preconception and pregnancy status, is assessed through obstetric and primary care; it is not part of Measura’s test library.

    Documentation and workflow

    Trigger criteria that follow from this evidence: age over 60, mild cognitive impairment or subjective cognitive complaint, “age-appropriate atrophy” on imaging, metformin at any duration, and two or more years of acid suppression. Encode them once so that screening does not depend on who is seeing the patient that day. The cognitive baseline, medication review and functional B12 result fit annual wellness visit integration, and the pattern behind a written baseline is discussed in what a cognitive baseline is for. The companion piece on functional B12 screening in metformin users covers the serum-marker evidence in depth, and every lifespan study, pregnancy data included, is collected in the Starved Brain evidence briefing for Chapter 6.

    Frequently asked questions

    Should every patient with mild cognitive impairment receive B vitamins?

    The trial data argue for measuring first. In VITACOG the atrophy benefit was concentrated in patients with high baseline homocysteine and absent at or below 9.5 µmol/L, and the Alzheimer’s trial that enrolled replete patients found no effect on decline. Homocysteine and functional B12 status identify who is likely to respond. Selection guidance is on who to test.

    Why did high-dose B vitamins fail in established Alzheimer’s disease?

    Two explanations fit the data. The disease may have been too advanced for tissue protection to matter, or the enrolled patients may simply not have been depleted, since all entered with normal folate, B12 and homocysteine. The trial cannot distinguish them, and both favor testing status earlier. The reasoning for measuring before diagnosis is on clinical rationale.

    Does long-term proton pump inhibitor use justify functional B12 testing?

    The evidence is mixed on average: a large case-control study found a dose gradient, while pooled reviews found a small or absent effect. In an older patient who may also have atrophic gastritis or take metformin, the exposures stack, and measurement is a low-burden way to resolve the individual case. Encoding that trigger is covered in standing orders for screening.

    How does this screening support quality documentation?

    A documented cognitive baseline, a functional B12 result with its medication context, and a fall-risk assessment create a structured record that supports value-based care reporting and follow-up at the next visit. The measures themselves are clinical; documentation makes them auditable over time. How this maps to quality programs is described in HEDIS and value-based care.

    Where does body composition testing fit for older adults?

    Sarcopenia accrues silently across decades, and body weight can stay stable while muscle declines. Measuring lean and fat compartments gives a concrete baseline alongside protein intake, which PROT-AGE sets at 1.0–1.2 g/kg/day or more for healthy adults over 65. The measurement is descriptive and goes to the treating physician. Practical workflow is on staffing and workflow.

    Can B vitamins slow brain shrinkage?

    In mild cognitive impairment, they did in the trial that tested it. In VITACOG, 271 people over 70 took high-dose B vitamins or placebo for two years. Whole-brain shrinkage ran 0.76% a year on the vitamins against 1.08% on placebo, and it was 53% lower in those who started with homocysteine above 13 µmol/L. A later analysis reported a cognitive benefit in that high-homocysteine group.

    Is serum B12 enough to test for deficiency after 60?

    No. In 548 Framingham survivors, methylmalonic acid was markedly raised in 11.3%, and the authors estimated metabolic deficiency at 12% or more, many of them with normal serum concentrations. The practice position is that serum B12 is not ordered alone in anyone over 60: methylmalonic acid or holotranscobalamin goes on the same order, with homocysteine and folate read beside them.

    Does metformin lower B12 in older adults?

    Yes, and randomization settled it. The Diabetes Prevention Program assigned 1,073 people to metformin and 1,082 to placebo. At five years, low-plus-borderline B12 occurred in 19.1% against 9.5%, and each year of use carried an odds ratio of 1.13. That is why metformin at any duration sits on the trigger list for functional B12 testing, alongside age over 60 and a cognitive complaint.

    Screen while the window is still open

    Learn how the Measura protocol fits a practice, from trigger criteria for older patients to a documented cognitive baseline.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE, 5(9), Article e12244. https://doi.org/10.1371/journal.pone.0012244
    • Aisen, P. S., Schneider, L. S., Sano, M., Diaz-Arrastia, R., van Dyck, C. H., Weiner, M. F., Bottiglieri, T., Jin, S., Stokes, K. T., Thomas, R. G., Thal, L. J., & Alzheimer Disease Cooperative Study. (2008). High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA, 300(15), 1774–1783. https://doi.org/10.1001/jama.300.15.1774
    • Hurwitz, A., Brady, D. A., Schaal, S. E., Samloff, I. M., Dedon, J., & Ruhl, C. E. (1997). Gastric acidity in older adults. JAMA, 278(8), 659–662. https://doi.org/10.1001/jama.1997.03550080069041
    • Krasinski, S. D., Russell, R. M., Samloff, I. M., Jacob, R. A., Dallal, G. E., McGandy, R. B., & Hartz, S. C. (1986). Fundic atrophic gastritis in an elderly population: Effect on hemoglobin and several serum nutritional indicators. Journal of the American Geriatrics Society, 34(11), 800–806. https://doi.org/10.1111/j.1532-5415.1986.tb03985.x
    • Andrès, E., Loukili, N. H., Noel, E., Kaltenbach, G., Abdelgheni, M. B., Perrin, A. E., Noblet-Dick, M., Maloisel, F., Schlienger, J.-L., & Blicklé, J.-F. (2004). Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ, 171(3), 251–259. https://doi.org/10.1503/cmaj.1031155
    • Lindenbaum, J., Rosenberg, I. H., Wilson, P. W., Stabler, S. P., & Allen, R. H. (1994). Prevalence of cobalamin deficiency in the Framingham elderly population. The American Journal of Clinical Nutrition, 60(1), 2–11. https://doi.org/10.1093/ajcn/60.1.2
    • Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435–2442. https://doi.org/10.1001/jama.2013.280490
    • Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., Crandall, J. P., & Diabetes Prevention Program Research Group. (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1754–1761. https://doi.org/10.1210/jc.2015-3754
    • Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., Visvanathan, R., Volpi, E., & Boirie, Y. (2013). Evidence-based recommendations for optimal dietary protein intake in older people: A position paper from the PROT-AGE Study Group. Journal of the American Medical Directors Association, 14(8), 542–559. https://doi.org/10.1016/j.jamda.2013.05.021
    • Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology, 14(10), 576–590. https://doi.org/10.1038/s41574-018-0059-4

    Related reading

  • Dr. Gurpreet Singh Padda beside the Chapter 5 title card of The Starved Brain reading Your Lab Says Normal. Your Brain Is Shrinking.

    Metformin B12 Deficiency: Screening Beyond the Serum Level

    Your Lab Says Normal. Your Brain Is Shrinking. | The Starved Brain, Chapter 5

    Metformin B12 Deficiency: Screening Beyond the Serum Level

    Metformin roughly doubles the risk of B12 deficiency, and serum B12 alone routinely misses it. Screening metformin users with a functional marker such as methylmalonic acid or homocysteine, or with holotranscobalamin, closes that gap.

    The patient most likely to be losing B12 is the metformin user, and that patient was nearly absent from the trial showing B vitamins slow brain atrophy.

    The chapter video, Your Lab Says Normal. Your Brain Is Shrinking., is aimed at patients, but its sharpest implication is for the clinician holding the requisition. Metformin B12 deficiency is common, dose- and duration-dependent, and routinely missed when serum B12 is the only marker ordered. The insulin-resistant patient on metformin is also nearly absent from the one randomized trial showing that B vitamins slow brain atrophy. That combination is a screening gap, and it closes with better ordering, not new technology.

    Is a normal serum B12 enough to rule out deficiency?

    In Oxford’s OPTIMA cohort, 107 cognitively normal adults aged 61–87 were scanned annually for five years. None had plasma B12 below 150 pmol/L. The bottom tertile, below 308 pmol/L, carried an adjusted OR of 6.17 (95% CI 1.25–30.47) for membership in the fastest-atrophying third; low holotranscobalamin, below 54 pmol/L, gave OR 5.99. Methylmalonic acid and homocysteine trended higher in fast losers but did not survive adjustment in a sample that small. In the Stockholm cohort of 501 adults aged 60 and over, each SD of higher B12 and holotranscobalamin predicted slower whole-brain loss and each SD of homocysteine predicted faster loss.

    The nulls deserve equal space. An Austrian cohort found no association between any B12 marker and atrophy, and the Dutch B-PROOF substudy found none with volume, though it scanned once and so measured volume rather than rate. The practice position is that the low-normal band matters clinically. That rests on the rate cohorts, not on any settled consensus, and it is stated here as a position.

    The size of that band in the general population is not trivial. Among 12,335 U.S. adults, 2.2% had serum B12 below 148 pmol/L and a further 13% sat between 148 and 222 pmol/L. For cognitive complaints specifically, total B12 discriminated deficiency with an AUC of 0.54, while holotranscobalamin reached 0.69. The test most often accepted as the answer performed close to chance for the indication that brings older patients in.

    How much does metformin lower B12, and do acid blockers add to it?

    Across 31 studies, metformin roughly doubled the risk of biochemical B12 deficiency (RR 2.09, 95% CI 1.49–2.93), with a mean fall of 63.70 pmol/L that scaled with dose and duration. In a randomized trial of 390 insulin-treated patients followed 4.3 years, metformin lowered B12 19% against placebo, one new deficiency per 13.8 patients treated. Five-year DPP follow-up put low-or-borderline status at 19.1% with metformin against 9.5% with placebo, each year of use carried OR 1.13, and neuropathy was more common in users with low levels.

    Acid suppression layers on top. In Kaiser Permanente data, two or more years of a proton pump inhibitor carried OR 1.65 for a deficiency diagnosis; a 2023 meta-analysis pooled a smaller 1.42 and judged the association unclear. Treat it as a contributor that stacks with metformin in the same older patient. None of this argues against metformin. It argues that a functional B12 result belongs on every metformin chart.

    The upstream driver is the food environment. A diet built on refined energy is low in both B12 and preformed EPA and DHA while it drives the insulin resistance that earns the metformin prescription. The system produces the deficiency, then prescribes the drug that deepens it, and the visit length leaves no room to connect the two.

    What VITACOG does and does not tell you

    In VITACOG, 271 patients with mild cognitive impairment, all aged 70 and over, were randomized to folic acid 0.8 mg, B12 0.5 mg and B6 20 mg daily or placebo for two years. Whole-brain atrophy ran 0.76% a year on treatment against 1.08% on placebo, 29.6% slower. Above a baseline homocysteine of 13.0 µmol/L the slowing was 53.3%; at or below 9.5 µmol/L there was none. Voxel-based analysis localized the protection to Alzheimer-vulnerable gray matter.

    The limits matter for your panel. Diabetes was rare: 10 placebo and 4 active participants in the imaging group, with faster atrophy that looked unresponsive on numbers too small to read. The trial was powered for atrophy, not cognition. The closest replication, in 279 Hong Kong outpatients, found no difference in its cognitive primary outcome and had no MRI endpoint. The investigators hold declared patents on this indication. And a retrospective subgroup analysis found the vitamins slowed atrophy 40.0% only in the top omega-3 tertile, with no significant effect in the bottom tertile.

    Dr. Padda treats B vitamins and omega-3 as a pair on the strength of those subgroups, a mirror-image result in the OmegAD trial and a tracer study, against one contradicting trial and no trial that randomized both. That is practicing ahead of the evidence, and the practice says so in writing rather than presenting the pairing as proven.

    What does an abnormal functional B12 result change?

    A raised methylmalonic acid or low holotranscobalamin with a normal serum B12 reclassifies the patient from reassured to insufficient, which changes the next decision. Homocysteine sorts who is likely to respond: the VITACOG investigators propose at or below 10 µmol/L as probably safe and 11 or above as possibly justifying intervention, a proposal from the same patent-holding group. Folate status has to be read beside B12. Once B12 fell below 148 pmol/L in national survey data, rising serum folate went with higher homocysteine and methylmalonic acid, and low B12 with high folate carried OR 2.6 for cognitive impairment in 1,459 older Americans. Across 25 trials, folic acid lowered homocysteine 23% and added B12 a further 7%, while three trials using 15 mg a day saw more cardiovascular events. More vitamin is not more benefit.

    Pairing the panel with cognition and nerve function

    Measura [Cardiometabolic and Autonomic Health Analysis] supplies the measurement layer and returns findings to the ordering physician; interpretation and management stay in your hands. Three pieces fit this patient. Laboratory panels carry whatever markers you specify, so the order can name methylmalonic acid, holotranscobalamin, homocysteine and folate beside serum B12. A cognitive assessment sets a documented baseline before any decline is clinically obvious, which is the only way to show later that a trajectory changed. Sudomotor testing quantifies small-fiber sudomotor output at the hands and feet, a distal autonomic readout that matters here because neuropathy tracked with low B12 among metformin users. It does not measure B12; it shows the nerve terrain in the same patient. The pairing with gait and falls risk is covered under cognitive assessment and fall prevention.

    Making it reproducible in the workflow

    Screening that depends on memory does not happen. A written protocol does. A reasonable trigger list from this evidence: any patient on metformin, two or more years of acid suppression, age over 60 with a cognitive complaint, and anyone whose serum B12 sits in the low-normal band. Build those into standing orders for screening so staff can queue functional markers without a separate decision each time; the rationale for that approach is laid out in making screening reproducible. The cognitive baseline and medication review both belong in annual wellness visit documentation. The companion post on B vitamins and the timing of mild cognitive impairment carries the argument into later life, and every cited study, with its limits, is collected in the Starved Brain evidence briefing for Chapter 5.

    Frequently asked questions

    Which patients should get functional B12 markers rather than serum B12 alone?

    The evidence supports prioritizing metformin users, patients with two or more years of acid suppression, older adults with cognitive complaints and anyone in the low-normal serum band. In those groups total B12 discriminates poorly, and methylmalonic acid, homocysteine and holotranscobalamin show whether the vitamin is working at the tissue level. Detailed selection criteria are on who to test.

    Does a low B12 on metformin mean the drug should change?

    Not on that basis. The metformin data describe a biochemical effect that is dose- and duration-dependent, and the sources frame it as a reason to monitor B12, not a case against the drug. Glycemic management and repletion decisions remain with the treating physician, weighed against the patient’s full metabolic picture. The broader reasoning behind measuring first is on clinical rationale.

    Is the omega-3 interaction strong enough to change practice?

    It is post hoc and hypothesis-generating: a retrospective subgroup of one trial, unadjusted for multiplicity, using plasma rather than red-cell omega-3. A mirror-image result in OmegAD supports it, and the FACIT folic acid analysis runs the other way. It is a reasonable argument for measuring both nutrient systems together rather than a proven rule. How paired markers appear in results is covered in interpreting the report.

    How should functional B12 results be documented?

    Record the marker, the value, where it sits relative to the reference interval, the medication context such as metformin or acid suppression, and the plan. Pairing the entry with the cognitive baseline lets the chart show a trajectory at the next review instead of isolated numbers. Structured result delivery into the record is described on getting results into the record.

    Does metformin cause B12 deficiency?

    Yes, and it is common. Across 31 studies, metformin roughly doubled the risk of biochemical B12 deficiency. In five-year Diabetes Prevention Program follow-up, low or borderline B12 ran at 19.1% with metformin against 9.5% with placebo, and neuropathy was more common in users with low levels. Serum B12 alone routinely misses it, which is why methylmalonic acid, homocysteine or holotranscobalamin belongs on the order.

    How quickly can metformin cause B12 deficiency?

    It builds with dose and time rather than overnight. Across 31 studies, the fall in B12 scaled with both. In a randomized trial that followed insulin-treated patients for 4.3 years, metformin lowered B12 19% against placebo. In Diabetes Prevention Program follow-up, each year of metformin use raised the odds of low or borderline B12 further. The longer the prescription, the stronger the case for a functional B12 result on the chart.

    Should I take B12 if I take metformin?

    Measure first, then decide. A functional B12 result belongs on every metformin chart: methylmalonic acid, homocysteine or holotranscobalamin, read beside serum B12 and folate. A raised methylmalonic acid or a low holotranscobalamin with a normal serum B12 changes the next decision. More vitamin is not more benefit, repletion stays with the treating physician, and none of this is a reason to stop metformin.

    Build functional B12 screening into your protocol

    Learn how the Measura protocol fits a practice, from standing orders for metformin patients to results that return to your chart.

    4477 Woodson Rd, Suite 201, St. Louis, MO 63134. Monday to Friday, 9:00 a.m. to 5:00 p.m. Please do not send symptoms, diagnoses or images through a web form — a website form is not a secure medical channel. Send your name and number and we will call you back.

    References

    • Vogiatzoglou, A., Refsum, H., Johnston, C., Smith, S. M., Bradley, K. M., de Jager, C., Budge, M. M., & Smith, A. D. (2008). Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology, 71(11), 826–832. https://doi.org/10.1212/01.wnl.0000325581.26991.f2
    • Mineva, E. M., Sternberg, M. R., Bailey, R. L., Storandt, R. J., & Pfeiffer, C. M. (2021). Fewer US adults had low or transitional vitamin B12 status based on the novel combined indicator of vitamin B12 status compared with individual, conventional markers, NHANES 1999-2004. The American Journal of Clinical Nutrition, 114(3), 1070-1079. https://doi.org/10.1093/ajcn/nqab122
    • Yang, W., Cai, X., Wu, H., & Ji, L. (2019b). Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: A meta-analysis. Journal of Diabetes, 11(9), 729–743. https://doi.org/10.1111/1753-0407.12900
    • de Jager, J., Kooy, A., Lehert, P., Wulffelé, M. G., van der Kolk, J., Bets, D., Verburg, J., Donker, A. J. M., & Stehouwer, C. D. A. (2010). Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: Randomised placebo controlled trial. BMJ, 340, c2181. https://doi.org/10.1136/bmj.c2181
    • Aroda, V. R., Edelstein, S. L., Goldberg, R. B., Knowler, W. C., Marcovina, S. M., Orchard, T. J., Bray, G. A., Schade, D. S., Temprosa, M. G., White, N. H., & Crandall, J. P., for the Diabetes Prevention Program Research Group (2016). Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1754–1761. https://doi.org/10.1210/jc.2015-3754
    • Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010). Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: A randomized controlled trial. PLoS ONE, 5(9), e12244. https://doi.org/10.1371/journal.pone.0012244
    • Jernerén, F., Elshorbagy, A. K., Oulhaj, A., Smith, S. M., Refsum, H., & Smith, A. D. (2015). Brain atrophy in cognitively impaired elderly: The importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial. The American Journal of Clinical Nutrition, 102(1), 215–221. https://doi.org/10.3945/ajcn.114.103283
    • Murphy, M. J., Brandie, F., Ebare, M., Harrison, M., Dow, E., Bartlett, W. A., & Craig, D. (2021). Personalising laboratory medicine in the ‘real world’: Assessing clinical utility, by clinical indication, of serum total B12 and Active-B12 (holotranscobalamin) in the diagnosis of vitamin B12 deficiency. Annals of Clinical Biochemistry, 58(5), 445–451. https://doi.org/10.1177/00045632211003605
    • Morris, M. S., Jacques, P. F., Rosenberg, I. H., & Selhub, J. (2007). Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. The American Journal of Clinical Nutrition, 85(1), 193–200. https://doi.org/10.1093/ajcn/85.1.193
    • Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435–2442. https://doi.org/10.1001/jama.2013.280490

    Related reading